MURFU Murphy Canyon Acquisition Corporation

 

As filed with the Securities and Exchange Commission on September 13, 2024

 

Registration No. 333-281933

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Pre-Effective Amendment No. 1

to

FORM S-1

REGISTRATION STATEMENT

Under

The Securities Act of 1933

 

CONDUIT PHARMACEUTICALS INC.

(Exact name of Registrant as specified in its charter)

 

Delaware		2834		87-3272543
(State or other jurisdiction of incorporation or organization)		(Primary Standard Industrial Classification Code Number)		(I.R.S. Employer Identification Number)

 

4995 Murphy Canyon Road, Suite 300

San Diego, CA 92134

(760) 471-8536

(Address, including zip code, and telephone number, including

area code, of Registrant’s principal executive offices)

 

David Tapolczay

Chief Executive Officer

Conduit Pharmaceuticals Inc.

4995 Murphy Canyon Road, Suite 300

San Diego, CA 92134

(760) 471-8536

(Name, address, including zip code, and telephone number, including

area code, of agent for service)

 

Copies of all communications, including communications sent to the agent for service, to:

 

Todd Mason, Esq.

Thompson Hine LLP

300 Madison Ave, 27th Floor

New York, NY 10017

(212) 344-5680

 

Approximate date of commencement of proposed sale to the public: From time to time after this registration statement becomes effective.

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. ☒

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Commission acting pursuant to said Section 8(a) may determine.

 

 

 

EXPLANATORY NOTE

 

This Pre-Effective Amendment No. 1 to the Registration Statement on Form S-1 of Conduit Pharmaceuticals Inc. (the “Company”) (File No. 333-281933) is being filed as an exhibit-only filing solely to amend Item 16 of Part II of the Registration Statement to file Exhibits 10.31 and 10.32. Accordingly, this Pre-Effective Amendment consists only of the facing page, this explanatory note, Part II of the Registration Statement, the signature pages to the Registration Statement, and the referenced exhibits. The prospectus constituting Part I of the Registration Statement is unchanged hereby and has been omitted.

 

 

PART II: INFORMATION NOT REQUIRED IN PROSPECTUS

 

Item 13. Other Expenses of Issuance and Distribution.

 

The following table sets forth the estimated expenses to be borne by the registrant in connection with the issuance and distribution of the shares of common stock and warrants being registered hereby.

 

SEC registration fee		$	420	(1)
Accounting fees and expenses		$	35,000
Legal fees and expenses		$	50,000
Miscellaneous expenses		$	4,580
Total		$	90,000

 

(1)

Previously paid.

 

Item 14. Indemnification of Directors and Officers.

 

Section 145 of the DGCL concerning indemnification of officers, directors, employees and agents is set forth below.

 

“Section 145. Indemnification of officers, directors, employees and agents; insurance.

 

(a)	A corporation shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person’s conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that the person’s conduct was unlawful.
(b)	A corporation shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys’ fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

 

(c)

(1)

To the extent that a present or former director or officer of a corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in subsections (a) and (b) of this section, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection therewith. For indemnification with respect to any act or omission occurring after December 31, 2020, references to “officer” for purposes of these paragraphs (c)(1) and (2) of this section shall mean only a person who at the time of such act or omission is deemed to have consented to service by the delivery of process to the registered agent of the corporation pursuant to § 3114(b) of Title 10 (for purposes of this sentence only, treating residents of this State as if they were nonresidents to apply § 3114(b) of Title 10 to this sentence).

 

 

(2)

The corporation may indemnify any other person who is not a present or former director or officer of the corporation against expenses (including attorneys’ fees) actually and reasonably incurred by such person to the extent he or she has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in subsections (a) and (b) of this section, or in defense of any claim, issue or matter therein.

 

(d)	Any indemnification under subsections (a) and (b) of this section (unless ordered by a court) shall be made by the corporation only as authorized in the specific case upon a determination that indemnification of the present or former director, officer, employee or agent is proper in the circumstances because the person has met the applicable standard of conduct set forth in subsections (a) and (b) of this section. Such determination shall be made, with respect to a person who is a director or officer of the corporation at the time of such determination, (1) By a majority vote of the directors who are not parties to such action, suit or proceeding, even though less than a quorum, or (2) By a committee of such directors designated by majority vote of such directors, even though less than a quorum, or (3) If there are no such directors, or if such directors so direct, by independent legal counsel in a written opinion, or (4) By the stockholders.
(e)	Expenses (including attorneys’ fees) incurred by an officer or director of the corporation in defending any civil, criminal, administrative or investigative action, suit or proceeding may be paid by the corporation in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined that such person is not entitled to be indemnified by the corporation as authorized in this section. Such expenses (including attorneys’ fees) incurred by former directors and officers or other employees and agents of the corporation or by persons serving at the request of the corporation as directors, officers, employees or agents of another corporation, partnership, joint venture, trust or other enterprise may be so paid upon such terms and conditions, if any, as the corporation deems appropriate.
(f)	The indemnification and advancement of expenses provided by, or granted pursuant to, the other subsections of this section shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person’s official capacity and as to action in another capacity while holding such office. A right to indemnification or to advancement of expenses arising under a provision of the certificate of incorporation or a bylaw shall not be eliminated or impaired by an amendment to or repeal or elimination of the certificate of incorporation or the bylaws after the occurrence of the act or omission that is the subject of the civil, criminal, administrative or investigative action, suit or proceeding for which indemnification or advancement of expenses is sought, unless the provision in effect at the time of such act or omission explicitly authorizes such elimination or impairment after such action or omission has occurred.

 

(g)

A corporation shall have power to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person’s status as such, whether or not the corporation would have the power to indemnify such person against such liability under this section. For purposes of this subsection, insurance shall include any insurance provided directly or indirectly (including pursuant to any fronting or reinsurance arrangement) by or through a captive insurance company organized and licensed in compliance with the laws of any jurisdiction, including any captive insurance company licensed under Chapter 69 of Title 18, provided that the terms of any such captive insurance shall:

 

(1)

Exclude from coverage thereunder, and provide that the insurer shall not make any payment for, loss in connection with any claim made against any person arising out of, based upon or attributable to any (i) personal profit or other financial advantage to which such person was not legally entitled or (ii) deliberate criminal or deliberate fraudulent act of such person, or a knowing violation of law by such person, if (in the case of the foregoing paragraph (g)(1)(i) or (ii) of this section) established by a final, nonappealable adjudication in the underlying proceeding in respect of such claim (which shall not include an action or proceeding initiated by the insurer or the insured to determine coverage under the policy), unless and only to the extent such person is entitled to be indemnified therefor under this section;

 

(2)

Require that any determination to make a payment under such insurance in respect of a claim against a current director or officer (as defined in paragraph (c)(1) of this section) of the corporation shall be made by a independent claims administrator or in accordance with the provisions of paragraphs (d)(1) through (4) of this section; and

 

(3)

Require that, prior to any payment under such insurance in connection with any dismissal or compromise of any action, suit or proceeding brought by or in the right of a corporation as to which notice is required to be given to stockholders, such corporation shall include in such notice that a payment is proposed to be made under such insurance in connection with such dismissal or compromise.

 

	For purposes of paragraph (g)(1) of this section, the conduct of an insured person shall not be imputed to any other insured person. A corporation that establishes or maintains a captive insurance company that provides insurance pursuant to this section shall not, solely by virtue thereof, be subject to the provisions of Title 18.
(h)	For purposes of this section, references to “the corporation” shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, and employees or agents, so that any person who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, shall stand in the same position under this section with respect to the resulting or surviving corporation as such person would have with respect to such constituent corporation if its separate existence had continued.
(i)	For purposes of this section, references to “other enterprises” shall include employee benefit plans; references to “fines” shall include any excise taxes assessed on a person with respect to any employee benefit plan; and references to “serving at the request of the corporation” shall include any service as a director, officer, employee or agent of the corporation which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner “not opposed to the best interests of the corporation” as referred to in this section.
(j)	The indemnification and advancement of expenses provided by, or granted pursuant to, this section shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of the heirs, executors and administrators of such a person.
(k)	The Court of Chancery is hereby vested with exclusive jurisdiction to hear and determine all actions for advancement of expenses or indemnification brought under this section or under any bylaw, agreement, vote of stockholders or disinterested directors, or otherwise. The Court of Chancery may summarily determine a corporation’s obligation to advance expenses (including attorneys’ fees).

 

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment of expenses incurred or paid by a director, officer or controlling person in a successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to the court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

 

 

Section 8.2 of the Company’s second amended and restated certificate of incorporation provides:

 

“(a) To the fullest extent permitted by applicable law, as the same exists or may hereafter be amended, the Corporation shall indemnify and hold harmless each person who is or was made a party or is threatened to be made a party to or is otherwise involved in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (a “proceeding”) by reason of the fact that he or she is or was a director or officer of the Corporation or, while a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, other enterprise or nonprofit entity, including service with respect to an employee benefit plan (an “indemnitee”), whether the basis of such proceeding is alleged action in an official capacity as a director, officer, employee or agent, or in any other capacity while serving as a director, officer, employee or agent, against all liability and loss suffered and expenses (including, without limitation, attorneys’ fees, judgments, fines, ERISA excise taxes and penalties and amounts paid in settlement) reasonably incurred by such indemnitee in connection with such proceeding. The Corporation shall to the fullest extent not prohibited by applicable law pay the expenses (including attorneys’ fees) incurred by an indemnitee in defending or otherwise participating in any proceeding in advance of its final disposition; provided, however, that, to the extent required by applicable law, such payment of expenses in advance of the final disposition of the proceeding shall be made only upon receipt of an undertaking, by or on behalf of the indemnitee, to repay all amounts so advanced if it shall ultimately be determined that the indemnitee is not entitled to be indemnified under this Section 8.2 or otherwise. The rights to indemnification and advancement of expenses conferred by this Section 8.2 shall be contract rights and such rights shall continue as to an indemnitee who has ceased to be a director, officer, employee or agent and shall inure to the benefit of his or her heirs, executors and administrators. Notwithstanding the foregoing provisions of this Section 8.2(a), except for proceedings to enforce rights to indemnification and advancement of expenses, the Corporation shall indemnify and advance expenses to an indemnitee in connection with a proceeding (or part thereof) initiated by such indemnitee only if such proceeding (or part thereof) was authorized by the Board.

 

(b) The rights to indemnification and advancement of expenses conferred on any indemnitee by this Section 8.2 shall not be exclusive of any other rights that any indemnitee may have or hereafter acquire under law, this Second Amended and Restated Certificate, the By-Laws, an agreement, vote of stockholders or disinterested directors, or otherwise.

 

(c) Any repeal or amendment of this Section 8.2 by the stockholders of the Corporation or by changes in law, or the adoption of any other provision of this Second Amended and Restated Certificate inconsistent with this Section 8.2, shall, unless otherwise required by law, be prospective only (except to the extent such amendment or change in law permits the Corporation to provide broader indemnification rights on a retroactive basis than permitted prior thereto), and shall not in any way diminish or adversely affect any right or protection existing at the time of such repeal or amendment or adoption of such inconsistent provision in respect of any proceeding (regardless of when such proceeding is first threatened, commenced or completed) arising out of, or related to, any act or omission occurring prior to such repeal or amendment or adoption of such inconsistent provision.

 

(d) This Section 8.2 shall not limit the right of the Corporation, to the extent and in the manner authorized or permitted by law, to indemnify and to advance expenses to persons other than indemnitees.”

 

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is theretofore unenforceable.

 

Item 15. Recent Sales of Unregistered Securities.

 

Since August 1, 2021, sales of the following unregistered securities have been made:

 

	●	On November 16, 2021, Murphy Canyon Acquisition Sponsor, LLC (the “Sponsor”) purchased 4,312,500 founder shares for an aggregate purchase price of $25,000, or approximately $0.006 per share.
	●	On February 7, 2022, simultaneously with the consummation of the Company’s initial public offering (the “SPAC IPO”), the Company consummated the private placement of 754,000 units (the “2022 Private Placement Units”) to the Sponsor, which amount includes 69,000 2022 Private Placement Units purchased by the Sponsor in connection with the underwriters’ exercise of a 45-day option to purchase additional units solely to cover over-allotments, at a price of $10.00 per 2022 Private Placement Unit, generating gross proceeds of approximately $7.54 million (the “2022 Private Placement”). A portion of the proceeds of were placed in the trust account and a portion was used to pay offering expenses including the non-deferred underwriting discount related to the SPAC IPO. No underwriting discounts or commissions were paid with respect to the 2022 Private Placement.

 

 

	●	In February 2022, we entered into an agreement with Cizzle Plc, whereby Cizzle Plc agreed to purchase a percentage of future revenue earned in an asset of ours related to COVID-19 (the “Covid Asset”), should the Covid Asset reach the commercialization stage. In December 2022, we entered into an agreement with Cizzle Plc whereby we granted Cizzle Plc the option, but not the obligation, to sell its economic interest in the Covid Asset back to us. The agreement contained an option period of nine months from the date of the agreement for Cizzle Biotechnology Holdings PLC (“Cizzle”) to notify us of its intent to exercise the option to sell its economic interest in the Covid Asset. Upon closing of the agreement, Cizzle agreed to pay the Company an option fee of $0.1 million (£0.1 million). In September 2023, Cizzle exercised its option under the agreement and, as a result, we issued 395,460 shares of Common Stock to Cizzle.
	●	In September 2023, concurrently with the completion of the Business Combination, the Company issued an aggregate of 2,000,000 units, with each unit consisting of one share of Common Stock (the “PIPE Shares”), together with one warrant exercisable into one share of Common Stock (the “PIPE Warrants”), at a purchase price of $10.00 per unit, for an aggregate purchase price of $20,000,000 (the “PIPE Financing”), pursuant to the terms of a subscription agreement, to Nirland Limited.   The PIPE Warrants are exercisable for a period of five years after the completion of the Business Combination and have an exercise price of $11.50 per share, subject to adjustment as set forth in the warrant for stock splits, stock dividends, recapitalizations and similar customary adjustments. The purchaser may exercise each PIPE Warrant on a cashless basis if the shares of Common Stock underlying the PIPE Warrants are not then registered pursuant to an effective registration statement. The purchaser contractually agreed to restrict its ability to exercise the PIPE Warrants such that the number of shares of the Common Stock held by the purchaser and its affiliates after such exercise does not exceed the beneficial ownership limitation set forth in the warrant which may not exceed 4.99% of the issued and outstanding shares of our Common Stock.
	●	On March 20, 2024, the Company issued in a private placement Common Stock purchase warrants to an unrelated third party to purchase up to an aggregate 260,000 shares of the Company’s Common Stock, in exchange for entering into a lock-up with respect to the shares of Common Stock held by such holder. The warrants are not exercisable until one year after their date of issuance. Each warrant is exercisable into one share of the Company’s Common Stock at a price per share of $3.18 (as adjusted from time to time in accordance with the terms thereof) for a two-year period after the date of exercisability. There is no established public trading market for the warrants. Notwithstanding the foregoing, the warrants shall vest, and not be subject to forfeiture, with respect to 25% of such warrants commencing on the 90th day after the date of the applicable lock-up agreement and 25% on each subsequent 90-day anniversary, in each case vesting only if the holder agrees to continue to have its shares of Common Stock remain locked up pursuant to the lock-up agreement on such date.

 

	●	On April 22, 2024, the Company issued in a private placement Common Stock purchase warrants (the “April Warrants”) to third parties, including certain directors, to purchase up to an aggregate of 907,725 shares of the Company’s Common Stock, in exchange for entering into a lock-up with respect to the shares of Common Stock held by such holder and for such directors, $0.125 per warrant.   The April Warrants are not exercisable until one year after their date of issuance. Each April Warrant is exercisable into one share of the Company’s Common Stock at a price per share of $3.12 (as adjusted from time to time in accordance with the terms thereof) for a two-year period after the date of exercisability. There is no established public trading market for the April Warrants.
	●	On June 24, 2024, in connection with a services agreement with an unrelated third party to provide marketing services, the Company issued 96,154 shares of its Common Stock (the “Service Shares”), having an aggregate value of $150,000.
	●	On August 6, 2024, the Company issued 9,504,465 shares of Common Stock to AstraZeneca as partial consideration for AstraZeneca’s grant to the Company of a license to certain intellectual property rights pursuant to the license agreement.
	●	On August 7, 2024, the Company issued 12,500,000 shares of Common Stock to Nirland as a closing fee pursuant to the Debt Agreements.

 

The foregoing securities were sold in transactions not involving an underwriter and not requiring registration under Section 5 of the Securities Act, in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act, and/or Regulation D promulgated thereunder.

 

 

Item 16. Exhibits and Financial Statement Schedules.

 

The financial statements filed as part of this registration statement are listed in the index to the financial statements immediately preceding such financial statements, which index to the financial statements is incorporated herein by reference.

 

Exhibit No.		Description
2.1		Agreement and Plan of Merger Agreement dated as of November 8, 2022, by and among Murphy Canyon Acquisition Corp., Conduit Merger Sub, Inc. and Conduit Pharmaceuticals Limited (filed as Annex A-1 to the Registrant’s Proxy Statement/Prospectus filed on August 11, 2023, and incorporated herein by reference).
2.2		Amendment to Agreement and Plan of Merger dated as of January 27, 2023, by and among Murphy Canyon Acquisition Corp., Conduit Merger Sub, Inc. and Conduit Pharmaceuticals Limited (filed as Annex A-2 to the Registrant’s Proxy Statement/Prospectus filed on August 11, 2023, and incorporated herein by reference).
2.3		Second Amendment to Agreement and Plan of Merger dated as of May 11, 2023, by and among Murphy Canyon Acquisition Corp., Conduit Merger Sub, Inc. and Conduit Pharmaceuticals Limited (filed as Annex A-3 to the Registrant’s Proxy Statement/Prospectus filed on August 11, 2023, and incorporated herein by reference).

 

3.1		Second Amended and Restated Certificate of Incorporation of the Registrant (filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on September 29, 2023, and incorporated herein by reference).
3.2		Amended and Restated Bylaws of the Registrant (filed as Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed on September 29, 2023, and incorporated herein by reference).
4.1		Specimen Common Stock Certificate of Conduit Pharmaceuticals Inc. (filed as Exhibit 4.8 to the Registrant’s Amendment No. 3 to Registration Statement on Form S-4 (File No. 333-271903) filed on August 8, 2023, and incorporated herein by reference).
4.2		Specimen Warrant Certificate of Conduit Pharmaceuticals Inc. (filed as Exhibit 4.9 to the Registrant’s Amendment No. 3 to Registration Statement on Form S-4 (File No. 333-271903) filed on August 8, 2023, and incorporated herein by reference).
4.3		Form of Senior Secured Promissory Note (filed as Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on August 7, 2024, and incorporated herein by reference).
5.1**		Opinion of Thompson Hine LLP.
10.1		Letter Agreement, dated February 2, 2022, among Murphy Canyon Acquisition Corp., Murphy Canyon Acquisition Sponsor, LLC, and each of the executive officers and directors of Murphy Canyon Acquisition Corp. (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on February 8, 2022, and incorporated herein by reference).
10.2		Underwriting Agreement (filed as Exhibit 1.1 to the Registrant’s Current Report on Form 8-K filed February 8, 2022, and incorporated herein by reference).
10.3		Promissory Note, dated November 4, 2021, issued to Murphy Canyon Acquisition Sponsor, LLC, by Murphy Canyon Acquisition Corp. (filed as Exhibit 10.2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-262036) filed on January 6, 2022, and incorporated herein by reference).
10.4		Investment Management Trust Agreement, dated February 2, 2022, between Murphy Canyon Acquisition Corp. and Wilmington Trust Company (filed as Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed on February 8, 2022, and incorporated herein by reference).
10.5		Registration Rights Agreement, dated February 2, 2022, among Murphy Canyon Acquisition Corp. and certain securityholders (filed as Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed on February 8, 2022, and incorporated herein by reference).
10.6		Securities Subscription Agreement, dated November 4, 2021, between Murphy Canyon Acquisition Corp. and Murphy Canyon Acquisition Sponsor, LLC (filed as Exhibit 10.5 to the Registrant’s Registration Statement on Form S-1 (File No. 333-262036) filed on January 6, 2022, and incorporated herein by reference).
10.7		Placement Unit Purchase Agreement, dated February 2, 2022, between Murphy Canyon Acquisition Corp. and Murphy Canyon Acquisition Sponsor, LLC (filed as Exhibit 10.4 to the Registrant’s Current Report on Form 8-K filed on February 8, 2022, and incorporated herein by reference).
10.8		Form of Conduit Pharmaceuticals Inc. Indemnity Agreement (filed as Exhibit 10.9 to the Registrant’s Current Report on Form 8-K filed on September 29, 2023, and incorporated herein by reference).
10.9		Administrative Support Agreement, dated February 2, 2022, by and between Murphy Canyon Acquisition Corp. and Murphy Canyon Management Group, Inc. (filed as Exhibit 10.6 to the Registrant’s Current Report on Form 8-K filed on February 8, 2022, and incorporated herein by reference).

 

 

10.10		Form of Lock-Up Agreement (filed as Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed on November 14, 2022, and incorporated herein by reference).
10.11		Sponsor Support Agreement, dated as of November 8, 2022, by and among Murphy Canyon Acquisition Corp. and each of the Persons set forth on Schedule I attached thereto (filed as Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed on November 14, 2022, and incorporated herein by reference).
10.12		Shareholder Support Agreement dated as of November 8, 2022, by and among Murphy Canyon Acquisition Corp., Conduit Pharmaceuticals Limited and each of the Persons set forth on Schedule I attached thereto (filed as Exhibit 10.4 to the Registrant’s Current Report on Form 8-K filed November 14, 2022, and incorporated herein by reference).
10.13		Form of Amended and Restated Warrant (filed as Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on January 30, 2023, and incorporated herein by reference).
10.14		Form of Note, issued March 7, 2023, by and between Murphy Canyon Acquisition Corp. and Murphy Canyon Acquisition Sponsor, LLC (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed March 7, 2023, and incorporated herein by reference).
10.15		Form of Subscription Agreement between Murphy Canyon Acquisition Corp. and the investor named therein (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on September 13, 2023, and incorporated herein by reference).
10.16		Form of PIPE Warrant (filed as Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on September 13, 2023, and incorporated herein by reference).
10.17#		Conduit Pharmaceuticals Inc. 2023 Stock Incentive Plan (filed as Annex C to the Registrant’s Proxy Statement/Prospectus filed on August 11, 2023, and incorporated herein by reference).
10.18#		Form of Stock Option Agreement under Conduit Pharmaceuticals Inc. 2023 Stock Incentive Plan (filed as Exhibit 10.17 to the Registrant’s Registration Statement on Form S-4 (File No. 333-271903) filed on May 12, 2023, and incorporated herein by reference).
10.19#		Form of Employment Agreement with David Tapolczay (filed as Exhibit 10.17 to the Registrant’s Amendment No. 2 to Registration Statement on Form S-4 (File No. 333-271903) filed on July 28, 2023, and incorporated herein by reference).
10.20#		Form of Employment Agreement with Adam Sragovicz (filed as Exhibit 10.18 to the Registrant’s Amendment No. 1 to Registration Statement on Form S-4 (File No. 333-271903) filed on July 11, 2023, and incorporated herein by reference).
10.21+		Exclusive Funding Agreement between St George Street Capital and SGS Global Limited, dated March 26, 2021 (filed as Exhibit 10.20 to the Registrant’s Registration Statement on Form S-4 (File No. 333-271903) filed on May 12, 2023, and incorporated herein by reference).
10.22+		AZD1656 Project Funding Agreement For Use In Renal Transplant between St George Street Capital Limited and Conduit Pharmaceuticals Limited, dated November 2, 2022 (filed as Exhibit 10.21 to the Registrant’s Registration Statement on Form S-4 (File No. 333-271903) filed on May 12, 2023, and incorporated herein by reference).
10.23+		AZD1656 Project Funding Agreement For Use In Preterm Labor between St George Street Capital Limited and Conduit Pharmaceuticals Limited, dated November 2, 2022 (filed as Exhibit 10.22 to the Registrant’s Registration Statement on Form S-4 (File No. 333-271903) filed on May 12, 2023, and incorporated herein by reference).

 

 

10.24+		AZD1656 Project Funding Agreement For Use In Hashimoto’s Thyroiditis between St George Street Capital Limited and Conduit Pharmaceuticals Limited, dated November 2, 2022 (filed as Exhibit 10.23 to the Registrant’s Registration Statement on Form S-4 (File No. 333-271903) filed on May 12, 2023, and incorporated herein by reference).
10.25+		AZD1656 Project Funding Agreement For Use In Uveitis between St George Street Capital Limited and Conduit Pharmaceuticals Limited, dated November 2, 2022 (filed as Exhibit 10.24 to the Registrant’s Registration Statement on Form S-4 (File No. 333-271903) filed on May 12, 2023, and incorporated herein by reference).
10.26+		AZD5904 Project Funding Agreement between St George Street Capital Limited and Conduit Pharmaceuticals Limited, dated November 2, 2022 (filed as Exhibit 10.25 to the Registrant’s Registration Statement on Form S-4 (File No. 333-271903) filed on May 12, 2023, and incorporated herein by reference).
10.27#		Consulting Agreement between with Jack Heilbron and Murphy Canyon Acquisition Corp. (filed as Exhibit 10.24 to the Registrant’s Amendment No. 1 to Registration Statement on Form S-4 (File No. 333-271903) filed on July 11, 2023, and incorporated herein by reference).
10.28#		Form of Non-Employee Director Compensation Program (filed as Exhibit 10.26 to the Registrant’s Amendment No. 2 to Registration Statement on Form S-4 (File No. 333-271903) filed on July 28, 2023, and incorporated herein by reference).
10.29#		Separation Agreement, dated May 12, 2024, between Mr. Sragovicz and Conduit Pharmaceuticals Inc. (filed as Exhibit 10.1 to the Registrations Quarterly Report on Form 10-Q filed on May 14, 2024, and incorporated herein by reference).
10.30		Security Agreement, dated August 6, 2024, between Nirland Limited and Conduit Pharmaceuticals Inc. (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on August 7, 2024, and incorporated herein by reference).
10.31*+		License Agreement, dated August 7, 2024, between AstraZeneca AB (PUBL) and Conduit Pharmaceuticals Inc.
10.32*+		Stock Issuance Agreement, dated August 7, 2024, between AstraZeneca AB (PUBL) and Conduit Pharmaceuticals Inc.
21.1		Subsidiaries of Conduit Pharmaceuticals Limited (filed as Exhibit 21.1 to the Registrant’s Amendment No. 2 to Registration Statement on Form S-4 (File No. 333-271903) filed on July 28, 2023, and incorporated herein by reference).
23.1**		Consent of Marcum LLP, independent public accounting firm of Conduit Pharmaceuticals Inc.
23.2**		Consent of Thompson Hine LLP (included in Exhibit 5.1 hereto).
24.1**		Power of Attorney.
107**		Filing Fee Table.

 

* Filed herewith.

** Previously filed.

# Management contract or compensatory plan or arrangement.

+ Certain portions of this Exhibit have been omitted in accordance with Item 601(b)(10) of Regulation S-K. The Registrant agrees to furnish supplementally an unredacted copy of this Exhibit to the SEC upon its request.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement on Form S-1/A to be signed on its behalf by the undersigned, in the city of San Diego, State of California, on September 13, 2024.

 

	CONDUIT PHARMACEUTICALS INC.
	By:	/s/ David Tapolczay
	Name:	David Tapolczay
	Title:	Chief Executive Officer

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.

 

Signature		Title		Date
/s/ David Tapolczay		Chief Executive Officer and Director		September 13, 2024
David Tapolczay		(Principal Executive Officer)
/s/ James Bligh		Interim Chief Financial Officer and Director		September 13, 2024
James Bligh		(Principal Financial Officer and Principal Accounting Officer)
*		Director and Chairperson of the Board of Directors		September 13, 2024
Freda Lewis-Hall
*		Director		September 13, 2024
Faith L. Charles
*		Director		September 13, 2024
Chele Chiavacci Farley
*		Director		September 13, 2024
Andrew Regan

 

By:	*/s/ David Tapolczay
	David Tapolczay
	Attorney-In-Fact

 

 

 

Exhibit 10.31

 

SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE SUCH TERMS ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THESE REDACTED TERMS HAVE BEEN MARKED IN THIS EXHIBIT WITH THREE ASTERISKS [***].

 

LICENSE AGREEMENT

 

between

 

ASTRAZENECA AB (PUBL)

 

and

 

CONDUIT PHARMACEUTICALS INC.

 

 

TABLE OF CONTENTS

 

ARTICLE 1 DEFINITIONS	1
ARTICLE 2 GRANT OF RIGHTS	12
ARTICLE 3 ASTRAZENECA’S RIGHT OF FIRST NEGOTIATION	14
ARTICLE 4 DEVELOPMENT, REGULATORY, AND COMMERCIALIZATION ACTIVITIES	15
ARTICLE 5 PAYMENTS AND RECORDS	20
ARTICLE 6 INTELLECTUAL PROPERTY	24
ARTICLE 7 CONFIDENTIALITY AND NON-DISCLOSURE	31
ARTICLE 8 REPRESENTATIONS AND WARRANTIES	35
ARTICLE 9 INDEMNITY	37
ARTICLE 10 TERM AND TERMINATION	39
ARTICLE 11 MISCELLANEOUS	47

 

 

LICENSE AGREEMENT

 

This License Agreement (this “Agreement”) is made and entered into effective as of August 7, 2024 (the “Effective Date”) by and between:

 

(1)	AstraZeneca AB (PUBL), a company incorporated in Sweden under no. 556011-7482 with offices at SE-431 83 Mölndal, Sweden (“AstraZeneca”); and

 

(2)	Conduit Pharmaceuticals Inc., a Delaware corporation with offices at 4995 Murphy Canyon Road, Suite 300, San Diego, California (“Licensee”).

 

AstraZeneca and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.

 

RECITALS

 

(A)	WHEREAS, AstraZeneca owns or Controls certain intellectual property rights with respect to the Licensed Compounds (as defined herein) in the Territory (as defined herein).

 

(B)	WHEREAS, AstraZeneca and [***] (“[***]”) are parties to a License Agreement dated 30 August 2019 (as amended, the “Earlier License Agreement”), pursuant to which AstraZeneca licensed to [***] rights relating to the Licensed Compounds known as AZD5904 and AZD1656.

 

(C)

WHEREAS, AstraZeneca and [***] entered into a letter agreement dated 24 May 2024 (the “[***] Letter Agreement”), pursuant to which AstraZeneca and [***] agreed to terminate the Earlier License Agreement subject to, and effective upon, completion of the transaction contemplated by this Agreement and AstraZeneca’s written notice thereof to [***].

 

(D)

WHEREAS, AstraZeneca wishes to grant a license to Licensee, and Licensee wishes to take a license under such intellectual property rights, to develop Licensed Compounds and Licensed Products, and to commercialize Licensed Products, in the Territory, in each case in accordance with the terms and conditions set forth below.

 

(E)	NOW, THEREFORE, in consideration of the premises and the mutual promises and conditions set forth herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows:

 

1.	DEFINITIONS

 

Unless otherwise specifically provided herein, the following terms shall have the following meanings:

 

1.1

“Affiliate” means, with respect to a Person, any Person that, directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control with such first Person at any time for so long as such Person controls, is controlled by or is under common control with such first Person. For purposes of this definition, “control” and, with correlative meanings, the terms “controlled by” and “under common control with” means: (a) the possession, directly or indirectly, of the power to direct the management or policies of a business entity, whether through the ownership of voting securities, by contract relating to voting rights or corporate governance or otherwise; or (b) the ownership, directly or indirectly, of more than fifty percent (50%) of the voting securities or other ownership interests of a business entity (or, with respect to a limited partnership or other similar entity, its general partner or controlling entity).

 

1.2

“Agreement” has the meaning set forth in the preamble hereto.

 

 

1.3

“Anti-Corruption Laws” means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act 2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money laundering or terrorism.

 

1.4

“Applicable Law” means applicable laws, rules and regulations, including any rules, regulations, guidelines or other requirements of any Governmental Authority or Regulatory Authorities, that may be in effect from time to time, including the FFDCA and the Anti-Corruption Laws as well as the Data Protection Laws.

 

1.5

“AstraZeneca” has the meaning set forth in the preamble hereto.

 

1.6

“AstraZeneca Indemnitees” has the meaning set forth in Section 9.1.

 

1.7

“AstraZeneca Know-How” means all Information relating to the Licensed Compounds that is (a) necessary for Licensee to Exploit the Licensed Compounds in the Field; or (b) contained within the Data Room, in each case ((a) or (b)) that is owned or Controlled by AstraZeneca or any of its Affiliates on the Effective Date, but excluding any information to the extent published in AstraZeneca Patents.

 

1.8

“AstraZeneca Patents” means the Patents and Patent applications set forth on Schedule 1.8 and any foreign counterparts thereof, as well as any Patents filed or claiming priority from such Patents or such foreign counterparts, but excluding any Joint Patents.

 

1.9

“Auditor” has the meaning set forth in Section 5.8.

 

1.10

“Breaching Party” has the meaning set forth in Section 10.2.2.

 

1.11

“Business Day” means a day other than a Saturday or Sunday or a day on which banking institutions in London, England, Stockholm, Sweden, or San Diego, California, U.S.A. are permitted or required to be closed.

 

1.12

“Calendar Quarter” means each successive period of three (3) calendar months commencing on January 1, April 1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the day immediately prior to the first to occur of January 1, April 1, July 1 or October 1 after the Effective Date and the last Calendar Quarter shall end on the last day of the Term.

 

1.13

“Calendar Year” means each successive period of twelve (12) calendar months commencing on January 1 and ending on December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of the year in which the Effective Date occurs and the last Calendar Year of the Term shall commence on January 1 of the year in which the Term ends and end on the last day of the Term.

 

 

1.14

“Commercially Reasonable Efforts” means, with respect to the performance of any activities with respect to any Licensed Compound(s) or Licensed Product(s), by or under the authority of Licensee, the carrying out of such activities in a sustained and diligent manner and using efforts and resources comparable to the efforts and resources commonly used in the biopharmaceutical industry for compounds or products of similar market potential at a similar stage of development or product life, but taking into account the size and resources of such Licensee, Affiliate, or Sublicensee, as applicable. “Commercially Reasonable Efforts” shall be determined without regard to any payments owed by Licensee to AstraZeneca under Article 5 of this Agreement.

 

1.15

“Confidential Information” has the meaning set forth in Section 7.1.

 

1.16

“Control” means, with respect to any item of Information, Regulatory Documentation, material, Patent or other intellectual property right, possession of the right, whether directly or indirectly and whether by ownership, license or otherwise (other than by operation of the license and other grants in Section 2.1), to grant a license, sublicense or other right (including the right to reference Regulatory Documentation) to or under such Information, Regulatory Documentation, material, Patent or other intellectual property right as provided for herein without violating the terms of any agreement with any Third Party.

 

1.17

“Corporate Names” means the corporate Trademarks, names, and logos of AstraZeneca and its Affiliates, and such other Trademarks, names, and logos as AstraZeneca may designate to Licensee in writing from time to time.

 

1.18

“Data Protection Laws” means all Applicable Law related to data protection including the Data Protection Act 2018 (DPA 2018), including the UK GDPR and Privacy and Electronic Communications (Amendments etc.) (EU Exit) Regulations 2019, the Privacy and Electronic Communications (EC Directive) Regulations 2003, the EU GDPR and any legislation implemented in connection with the aforementioned legislation, each as amended supplemented or replaced from time to time.

 

1.19

“Data Room” means the virtual data room hosted by AstraZeneca.

 

1.20

“Development Plan” has the meaning set out in Section 4.2.

 

1.21

“Disclosing Party” has the meaning set forth in Section 7.1.

 

1.22

“Dispute” has the meaning set forth in Section 11.5.1.

 

 

1.23

“Distributor” means a Third Party (other than a Sublicensee) appointed by Licensee or its Affiliate or Sublicensee to market and sell Licensed Product(s) in circumstances where such Third Party purchases its requirements of such Licensed Product(s) from Licensee, its Affiliate or Sublicensee and does not otherwise make any royalty payments or other payments to Licensee, its Affiliates or Sublicensee with respect to intellectual property rights relating to the Licensed Product(s).

 

1.24

“Dollars” or “$” means United States Dollars.

 

1.25

“Drug Approval Application” means a New Drug Application as defined in the FFDCA (“NDA”) or any corresponding foreign application in the Territory, including, with respect to the European Union, a Marketing Authorization Application (“MAA”) filed with the EMA pursuant to the centralized approval procedure or with the applicable Regulatory Authority of a country in Europe with respect to the mutual recognition or any other national approval.

 

1.26

“Earlier License Agreement” has the meaning set forth in the Recitals hereto.

 

1.27

“Effective Date” has the meaning set forth in the preamble hereto.

 

1.28

“EMA” means the European Medicines Agency and any successor agency thereto.

 

1.29

“European Union” means the economic, scientific and political organization of European Union member states as it may be constituted from time to time, specifically including any country that was a European Union member state as of the Effective Date, whether or not such country is a participating member as of the applicable time.

 

1.30

“Exercise Period” has the meaning set forth in Section 3.2.

 

1.31

“Exploit” means to make, have made, import, use, sell or offer for sale, including to research, develop, commercialize, register, Manufacture, have Manufactured, hold or keep (whether for disposal or otherwise), have used, export, transport, distribute, promote, market or have sold or otherwise dispose of a compound or product. “Exploitation” means the act of Exploiting a compound or product.

 

1.32

“FDA” means the United States Food and Drug Administration and any successor agency thereto.

 

1.33

“FFDCA” means the United States Federal Food, Drug, and Cosmetic Act, as amended from time to time, together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions and modifications thereto).

 

 

1.34

“Field” means the treatment, prevention, and prophylaxis of Idiopathic Male Infertility for AZD5904, and all therapeutic, prophylactic, palliative and diagnostic uses in humans and animals for AZD1656 and AZD5658.

 

1.35

“First Commercial Sale” means the first sale for monetary value for use or consumption by the end user of a Licensed Product in any country of the Territory after approval of a Drug Approval Application for such Licensed Product has been obtained in such country. Sales prior to approval of a Drug Approval Application for such Licensed Product in such country, such as so-called “treatment IND sales,” “named patient sales,” and “compassionate use sales,” shall not be construed as a First Commercial Sale.

 

1.36

“Governmental Authority” means (a) any nation or government, including any federal, state, local, foreign, municipality, principality, commonwealth, province, territory, county, district or other jurisdiction of any nature or other political subdivision thereof; or (b) any supranational, international, federal, state or local entity, department, commission, bureau, agency, authority, board, court, official or officer, domestic or foreign, exercising executive, judicial, regulatory, administrative, judicial, police, military, or taxing governmental functions, domestic or foreign, including FDA.

 

1.37

“Gross Revenue” has the meaning set forth in Section 1.87.

 

1.38

“IFRS” means the International Financial Accounting Reporting Standards, as amended from time to time by the International Accounting Standards Board.

 

1.39

“IND” means (a) an investigational new drug application filed with the FDA for authorization to commence clinical studies or any corresponding foreign application in the Territory and (b) all supplements and amendments that may be filed with respect to the foregoing.

 

1.40

“Indemnification Claim Notice” has the meaning set forth in Section 9.3.

 

1.41

“Indemnified Party” has the meaning set forth in Section 9.3.

 

1.42

“Information” means all technical, scientific and other data, know-how and information, including trade secrets, specifications, biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, pre-clinical, clinical, safety, Manufacturing and quality control data and information, including study designs and protocols, assays and biological methodology, in each case (whether or not confidential, proprietary, patented or patentable) in written, electronic or any other form now known or hereafter developed.

 

1.43

“Infringement” has the meaning set forth in Section 6.5.1.

 

 

1.44

“Intellectual Property Rights” means Patents, utility models, rights to inventions, copyright and related rights, Trademarks, business names and domain names, goodwill and the right to sue for infringement or misappropriation, rights in designs, rights in computer software, database rights, know-how, rights to use and protect the confidentiality of confidential information and all other intellectual property rights, in each case whether registered or unregistered and including all applications and rights to apply for and be granted, renewals or extensions of, and rights to claim priority from, such rights and all similar or equivalent rights or forms of protection which subsist or will subsist now or in the future in any part of the world and the right to apply for and be granted the foregoing.

 

1.45

“Inventory” has the meaning set forth in Section 4.11.1.

 

1.46

“Joint Intellectual Property Rights” has the meaning set forth in Section 6.1.2.

 

1.47

“Joint Know-How” has the meaning set forth in Section 6.1.2.

 

1.48

“Joint Patents” has the meaning set forth in Section 6.1.2.

 

1.49

“Licensed Compound(s)” means: (i) the pharmaceutical compounds known individually and together as AZD1656, AZD5658 and AZD5904; and (ii) any metabolite, salt, ester, hydrate, solvate, isomer, enantiomer, free acid form, free base form, crystalline form, co-crystalline form, amorphous form, pro-drug (including ester pro-drug) form, racemate, polymorph, chelate, stereoisomer, tautomer, or optically active form of the foregoing compounds under this Section 1.49.

 

1.50

“Licensed Product” means any product that is comprised of or contains a Licensed Compound, alone or in combination with one or more other active ingredients, in any and all forms, presentations, dosages and formulations.

 

1.51

“Licensed Product Agreement” means, with respect to a Licensed Product, any agreement entered into by and between Licensee or any of its Affiliates or its or their respective Sublicensees, on the one hand, and one or more Third Parties, on the other hand, that is necessary or reasonably useful for the Exploitation of such Licensed Product in the Field in the Territory, including (a) any agreement pursuant to which Licensee, its Affiliates or its or their Sublicensees receives any license or other rights to Exploit such Licensed Product, (b) supply agreements pursuant to which Licensee, its Affiliates or its or their Sublicensees obtain or will obtain quantities of such Licensed Product, (c) clinical study agreements, (d) contract research organization agreements and (e) service agreements.

 

 

1.52

“Licensee” has the meaning set forth in the preamble hereto.

 

1.53

“License Effective Date” has the meaning set forth in Section 2.1.

 

1.54

“Licensee Indemnitees” has the meaning set forth in Section 9.2.

 

1.55

“Licensee Know-How” means all Information Controlled by Licensee or any of its Affiliates or its or their Sublicensees as of the Effective Date or that is generated by or on behalf of Licensee or any of its Affiliates under or in connection with this Agreement during the Term that is (a) not generally known and (b) necessary for the Exploitation of the Licensed Compounds or Licensed Products in the Field, but excluding any Information to the extent covered or claimed by published Licensee Patents or Joint Patents or any Joint Know-How.

 

1.56

“Licensee Patents” means all of the Patents Controlled by Licensee or any of its Affiliates as of the Effective Date or at any time during the Term that are necessary (or, with respect to Patent applications, would be necessary if such Patent applications were to issue as Patents) for the Exploitation of the Licensed Compounds or Licensed Products in the Field, but excluding any Joint Patents. Licensee Patents include the Co-Crystal Patents set out in Schedule 1.56, and any foreign counterparts thereof, as well as any Patents filed or claiming priority from such Patents or such foreign counterparts”.

 

1.57

“Licensee Triggered Termination” has the meaning set forth in Section 10.4.1(c).

 

1.58

“Losses” has the meaning set forth in Section 9.1.

 

1.59

“MAA” has the meaning set forth in the definition of “Drug Approval Application”.

 

1.60

“Major Markets” means the United States, the UK, Germany, France, Italy, Spain, Japan and China.

 

1.61

“Manufacture” and “Manufacturing” means all activities related to the production, manufacture, processing, filling, finishing, packaging, labelling, shipping and holding of a product or any intermediate thereof, including process development, process qualification and validation, scale-up, pre-clinical, clinical and commercial manufacture and analytic development, product characterization, stability testing, quality assurance and quality control.

 

1.62

“NDA” has the meaning set forth in the definition of “Drug Approval Application.”

 

1.63

“Negotiation Period” has the meaning set forth in Section 3.3.

 

1.64

“Non-Breaching Party” has the meaning set forth in Section 10.2.1.

 

1.65

“Non-Prosecuting Party” has the meaning set forth in Section 6.2.2.

 

 

1.66

“Notice Period” has the meaning set forth in Section 10.2.1.

 

1.67

“Party” and “Parties” have the meanings set forth in the preamble hereto.

 

1.68

“Patents” means: (a) all national, regional and international patents and patent applications, including provisional patent applications; (b) all patent applications that claim priority to any patent or patent application in clause (a), including divisionals, continuations, continuations-in-part, provisionals, converted provisionals and continued prosecution applications; (c) any and all patents that have issued or in the future issue from the foregoing patent applications ((a) and (b)), including utility models, petty patents, innovation patents and design patents and certificates of invention; and (d) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, re-examinations or any other post-grant proceedings and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patent applications ((a), (b) and (c)).

 

1.69

“Payment” has the meaning set forth in Section 5.6.1.

 

1.70

“Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or political subdivision, department or agency of a government.

 

1.71

“Personal Data” means any information that: (i) relates to an identified or identifiable natural person (an identifiable natural person is one who can be identified, directly or indirectly, in particular by reference to an identification number); and/or (ii) constitutes “personal data”, “personal information”, “personally identifiable information” or similar term defined in applicable Data Protection Laws.

 

1.72

“POC Study” means a clinical phase 2 clinical trial of a Licensed Compound that is intended to generate initial evidence of clinical efficacy and safety in the target population.

 

1.73

“Product Trademark” means the Trademark used or to be used by Licensee or its Affiliates or its or their Sublicensees in the commercialization of a Licensed Product in the Territory (excluding, in any event, any Corporate Names and any other Trademarks that consist of or include any corporate name or corporate logo of either Party or any of its Affiliates or its or their (sub) licensees (or Sublicensees)).

 

1.74

“Prosecuting Party” has the meaning set forth in Section 6.2.2.

 

1.75

“Receiving Party” has the meaning set forth in Section 7.1.

 

 

1.76

“Regulatory Approval” means, with respect to a country in the Territory, any and all approvals (including Drug Approval Applications), licenses, registrations or authorizations of any Regulatory Authority necessary to commercially distribute, sell or market a Licensed Product in such country, including, where applicable, (a) pricing or reimbursement approval in such country, (b) pre- and post-approval marketing authorizations (including any prerequisite Manufacturing approval or authorization related thereto) and (c) labelling approval.

 

1.77

“Regulatory Authority” means any applicable supra-national, federal, national, regional, state, provincial or local regulatory agencies, departments, bureaus, commissions, councils or other government entities regulating or otherwise exercising authority with respect to the Exploitation of the Licensed Compounds or a Licensed Product in the Territory, including the FDA in the United States and the EMA in the European Union.

 

1.78

“Regulatory Documentation” means: all (a) applications (including all INDs and Drug Approval Applications), registrations, licenses, authorizations and approvals (including Regulatory Approvals); and (b) correspondence and reports submitted to or received from Regulatory Authorities (including minutes and official contact reports relating to any communications with any Regulatory Authority) and all supporting documents with respect thereto, including all adverse event files and complaint files, in each case ((a) and (b)) relating to the Licensed Compounds or a Licensed Product.

 

1.79

“Relevant Transaction” has the meaning set forth in Section 3.1.

 

1.80

“Relevant Transaction Notice” has the meaning set forth in Section 3.1.

 

1.81

“Representatives” has the meaning set forth in Section 8.6.

 

1.82

“Senior Officer” means, with respect to AstraZeneca, its Senior Vice President, Early CVRM, BioPharmaceuticals and with respect to Licensee, its Chief Executive Officer.

 

1.83

“[***]” has the meaning set forth in the Recitals hereto.

 

 

1.84

“[***] Letter Agreement” has the meaning set forth in the Recitals hereto.

 

1.85

“Sublicense” has the meaning set forth in Section 2.2.

 

1.86

“Sublicensee” means a Third Party that is granted a Sublicense, and who has undertaken to make a royalty payment or other payment to Licensee, its Affiliates or Sublicensee in consideration of such Sublicense (or who is subject to other contractual arrangements with Licensee, its Affiliates or Sublicensee, whereby Licensee, its Affiliate or Sublicensee share in the profits or has an equivalent interest in the proceeds from the sale of Licensed Product(s) by such Third Party). For clarity, any Third Party to which a Sublicensee grants a further sublicense (where a Sublicense is granted through multiple tiers) shall also be a Sublicensee hereunder. A Third Party that (i) is granted a Sublicence solely to enable such Third Party to provide contract research or development services or contract manufacturing services for Licensee or its Affiliates, and (ii) does not have the right to distribute, market, promote or sell the Licensed Products shall not be a “Sublicensee” for the purposes of this Agreement.

 

1.87

“Sublicense Revenue” means consideration [***].

 

1.88

“Tax” or “Taxes” means all taxes of any kind, and all charges, fees, customs, levies, duties, imposts, required deposits or other assessments, including all federal, state, local or foreign net income, capital gains, gross income, gross receipt, property, franchise, sales, use, excise, withholding, payroll, employment, social security, worker’s compensation, unemployment, occupation, capital stock, transfer, gains, windfall profits, net worth, asset, transaction and other taxes, and any interest, penalties or additions to tax with respect thereto, imposed upon any Person by any Taxing Authority or other Governmental Authority under Applicable Law, whether disputed or not, and including any obligation to indemnify or otherwise assume or succeed to the Tax liability of any other Person by Applicable Law, by contract or otherwise.

 

 

1.89

“Tax Evasion” means (a) fraudulently or dishonestly failing to pay any amount of Tax in connection with or attributable to this Agreement or the transactions contemplated hereby to the relevant Taxing Authority within any applicable time limit for the payment of such Tax without incurring interest and/or penalties or (b) fraudulently or dishonestly claiming any relief, allowance, credit, deduction, exemption or set off in respect of any Tax in connection with or attributable to this Agreement or the transactions contemplated hereby (or relevant to the computation of any income, profits or gains for the purposes of any such Tax), or any right to or actual repayment of or saving of such Tax.

 

1.90

“Taxing Authority” means any Governmental Authority or any subdivision, agency, commission or authority thereof or any quasi-governmental body exercising tax regulatory authority.

 

1.91

“Term” has the meaning set forth in Section 10.1.

 

1.92

“Termination Notice” has the meaning set forth in Section 10.2.1.

 

1.93

“Territory” means the entire world.

 

1.94

“Third Party” means any Person other than AstraZeneca, Licensee and their respective Affiliates.

 

1.95

“Third Party Claims” has the meaning set forth in Section 9.1.

 

1.96

“Third Party Infringement Claim” has the meaning set forth in Section 6.6.

 

1.97

“Third Party Patent Right” has the meaning set forth in Section 6.9.

 

 

1.98

“Top Line Data” means data contained in data reports following completion of the dose escalation portion of a POC Study that includes the primary and secondary efficacy results and adverse event summary for safety.

 

1.99

“Trademark” means any word, name, symbol, colour, designation or device or any combination thereof that functions as a source identifier, including any trademark, trade dress, brand mark, service mark, trade name, brand name, logo or business symbol, whether or not registered.

 

1.100

“Transition Plan” has the meaning set forth in Section 2.4.

 

1.101

“United States” or “U.S.” means the United States of America and its territories and possessions (including the District of Columbia and Puerto Rico).

 

1.102

“Upfront Payment” has the meaning set forth in Section 5.1.1.

 

1.103

“VAT” means, within the European Union, such Taxes as may be levied in accordance with Council Directive 2006/112/EC and, outside the European Union, any Taxes levied by reference to added value, consumption or sales.

 

2.	GRANT OF RIGHTS and Transition ACTIVITIES

 

2.1

License Grant. Subject to Section 2.5 and to the other terms and conditions of this Agreement, effective upon (and not before) AstraZeneca’s receipt of the Upfront Payment in accordance with Section 5.1.1 (the “License Effective Date”), AstraZeneca hereby grants to Licensee an exclusive (including with regard to AstraZeneca and its Affiliates) license, with the right to grant sublicenses in accordance with Section 2.2, under the AstraZeneca Patents, the AstraZeneca Know-How, and AstraZeneca’s interests in the Joint Patents and the Joint Know-How, solely for the purpose of Exploiting the Licensed Compounds and Licensed Products in the Field in the Territory.

 

2.2

Sublicenses. Subject to AstraZeneca’s right of first negotiation under Article 3, Licensee shall have the right to grant sublicenses (or further rights of reference), through multiple tiers of sublicensees, under the license granted in Section 2.1, to its Affiliates and Third Parties in respect of Licensed Compounds (each such sublicense, a “Sublicense”), provided that (a) any Sublicenses granted by Licensee shall be consistent with, and expressly made subject and subordinate to, the terms and conditions of this Agreement and (b) Licensee shall provide a near final version of the sublicense agreement to AstraZeneca prior to execution (such agreement to be treated as Confidential Information of Licensee). Licensee shall cause each of its Affiliates and Sublicensees to comply with the applicable terms and conditions of this Agreement, as if such Affiliate and Sublicensee were a Party to this Agreement. Licensee hereby guarantees the performance of its Affiliates and Sublicensees and the grant of any such Sublicense shall not relieve Licensee of its obligations under this Agreement, except to the extent they are satisfactorily performed by such Affiliate or Sublicensee. Licensee shall provide AstraZeneca with a copy of any sublicense agreement executed by Licensee within fourteen (14) days after its execution; provided that the financial terms of any such sublicense agreement to the extent not pertinent to an understanding of a Party’s obligations or benefits under this Agreement may be redacted. Notwithstanding anything else set out in this Agreement, Licensee shall disclose to AstraZeneca all terms of any sublicense agreement and any other documentation, records or information associated with a Sublicense that are necessary for AstraZeneca to determine or calculate the Sublicense Revenue.

 

2.3

No Implied License or Other Rights Granted by AstraZeneca. Except as expressly provided herein, AstraZeneca grants Licensee no other right or license, including any rights or licenses to the AstraZeneca Patents, the AstraZeneca Know-How, AstraZeneca’s interest in the Joint Patents and the Joint Know-How or any other Patent, Trademark or other intellectual property rights. For the avoidance of doubt, nothing in this Agreement shall prevent AstraZeneca, its Affiliates, or any Third Parties engaged by AstraZeneca or its Affiliates, from Exploiting the Licensed Compounds in any field other than the Field.

 

 

2.4

Transition of Know-How.

 

2.4.1

AstraZeneca shall – within sixty (60) days after AstraZeneca’s receipt of the Upfront Payment in accordance with Section 5.1.1 – provide (and/or procure that its Affiliates provide) to Licensee or its nominee any AstraZeneca Know-How to the extent such AstraZeneca Know-How is reasonably available to AstraZeneca in electronic form. AstraZeneca shall notify Licensee in writing when AstraZeneca has completed its provision of such AstraZeneca Know-How to Licensee (such notice, an “AZ Completion Notice”). If Licensee believes that any AstraZeneca Know-How that should have been provided pursuant to this Section 2.4.1 has not been provided to it, Licensee may notify AstraZeneca thereof in writing within sixty (60) days following the date of the AZ Completion Notice (the “Request Period”). Licensee shall not be entitled to request any further AstraZeneca Know-How after expiry of the Request Period and AstraZeneca shall have no obligation to provide any further AstraZeneca Know-How unless requested within the Request Period. For the avoidance of doubt AstraZeneca shall have no obligation to transfer any AstraZeneca Know-How to Licensee other than pursuant to this Section 2.4.1.

 

2.4.2

Notwithstanding anything else set out in this Agreement, AstraZeneca has no obligations to procure the assignment, transfer, grant or provision of any rights, Information, materials, services or other things relating to any of the Licensed Compounds or Licensed Products by or from [***] to Licensee. Licensee acknowledges and agrees that it shall be solely responsible for negotiating directly with [***] regarding any such assignment, transfer, grant or provision.

 

2.5

Data Privacy and Cyber Security.

 

2.5.1

The Parties shall comply with the terms set out in Schedule 2.5.1 (Data Protection and Security Requirements), which reflect the agreements that the Parties put in place to facilitate the processing and sharing of Personal Data between the Parties, both acting as separate Data Controllers (as defined in Schedule 2.5.1), explain the purposes for which the Personal Data may be used and define the principles that the Parties shall adhere to and the responsibilities of the Parties to each other.

 

2.5.2

The Parties will each maintain adequate administrative, technical, and physical measures, controls, tools, systems, policies, and procedures in accordance with good cyber security industry practices and sufficient to perform their respective obligations under this Agreement. Without limitation of the foregoing Licensee will comply with the requirements set out in Schedule 2.5.2 (Cyber Security Requirements) and Schedule 2.5.2(a) (IT Risk Mitigation Requirements).

 

2.6

Retained Rights. Notwithstanding Section 2.1, AstraZeneca, on behalf of itself and its Affiliates, retains the right to (a) conduct and complete the ongoing studies or other activities involving the Licensed Compounds that are listed in Schedule 2.6 and (b) continue to use the AstraZeneca Know-How or conduct activities involving the Licensed Compounds and Licensed Products as may be necessary or useful to exercise its or its Affiliates’ respective rights or perform its or its Affiliates’ respective obligations under or pursuant to this Agreement. For the avoidance of doubt, AstraZeneca, on behalf of itself and its Affiliates, retains the right to Exploit the Licensed Compounds and Licensed Products outside the Field.

 

2.7

Termination of Earlier License Agreement. AstraZeneca shall, within two (2) Business Days of the License Effective Date, terminate the Earlier License Agreement.

 

 

3.	ASTRAZENECA’S RIGHT OF FIRST NEGOTIATION

 

3.1

Upon Licensee or its Affiliate (a) receiving an offer from a Third Party pursuant to which such Third Party would obtain the right (via license/sublicense, assignment or otherwise) to develop, Manufacture or commercialize a Licensed Product (other than as a (i) Distributor or (ii) contract research organisation, contract development/manufacturing organisation or similar on behalf of Licensee purely on a fee for service basis) or (b) deciding to solicit an offer for, or enter into an agreement of, the scope set out in (a) above (in each case, (a) or (b), such transaction a “Relevant Transaction”), Licensee shall provide written notice thereof to AstraZeneca in writing (a “Relevant Transaction Notice”) promptly following the occurrence of an event described in paragraphs (a) or (b) above. The Relevant Transaction Notice shall include such information within Licensee’s possession and Control as may reasonably be required or useful for AstraZeneca to determine its interest in the Relevant Transaction, subject to compliance by the Licensee with any confidentiality and other contractual undertakings previously entered into between the Licensee and any relevant Third Party.

 

3.2

For a period of [***] following receipt of a Relevant Transaction Notice (the “Exercise Period”) AstraZeneca shall have the exclusive right to negotiate, and if agreed, enter into, an agreement with Licensee of the same scope as the Relevant Transaction. Until the expiry of the Exercise Period and, if applicable, the Negotiation Period, Licensee shall not negotiate with any Third Party regarding such Relevant Transaction (or the Licensed Product within the scope of such Relevant Transaction), provided that Licensee may inform any Third Party from whom it receives an offer or expression of interest in relation to a Relevant Transaction that it is subject to an exclusive negotiation obligation and the duration of such obligation (but not that such obligation is to AstraZeneca).

 

3.3

If within the Exercise Period AstraZeneca notifies Licensee in writing that it wants to exercise its right of first negotiation pursuant to this Article 3 (an “Exercise Notice”), the Parties agree to negotiate in good faith for a maximum period of [***] from the date of the Exercise Notice (the “Negotiation Period”) to enter into a definitive agreement of the same scope as the Relevant Transaction. During the Negotiation Period, Licensee shall not, and shall cause its Affiliates not to, initiate discussions – or enter into an agreement – with any Third Party regarding the Relevant Transaction (or the Licensed Product within the scope thereof). If a definitive agreement regarding the Relevant Transaction is not agreed between Licensee or its Affiliate on one hand and AstraZeneca or its Affiliate on the other hand within the Negotiation Period, Licensee shall have no further obligations to AstraZeneca (and AstraZeneca no further rights) regarding such Relevant Transaction and Licensee may negotiate and enter into an agreement with a Third Party for such Relevant Transaction, provided, however, that any agreement entered into by and between Licensee or its Affiliate and a Third Party must be consistent with the terms of this Agreement.

 

 

3.4

If, within the Exercise Period, AstraZeneca: (a) fails to provide an Exercise Notice to Licensee; or, (b) notifies Licensee in writing that it does not want to exercise its right of first negotiation pursuant to this Article 3, then Licensee shall have no further obligations to AstraZeneca (and AstraZeneca no further rights) regarding such Relevant Transaction and Licensee may negotiate and enter into an agreement with a Third Party regarding such Relevant Transaction, provided, however, that any such agreement with a Third Party must be consistent with the terms of this Agreement.

 

3.5

For the avoidance of doubt, AstraZeneca shall have a separate right of first negotiation pursuant to this Article 3 for each Licensed Product and neither Licensee nor its Affiliates shall approach or negotiate with a Third Party regarding a different Relevant Transaction or a different Licensed Product, without first having complied with the steps set out in this Article 3.

 

4.	DEVELOPMENT, REGULATORY, AND COMMERCIALIZATION ACTIVITIES

 

4.1

Development. Subject to AstraZeneca’s right of first negotiation under Article 3, and the other terms and conditions of this Agreement, Licensee shall have the right and the obligation to develop each Licensed Compound in the Field in the Territory at its sole cost and expense in accordance with the Development Plan. Licensee shall perform or cause to be performed its development activities hereunder in good scientific manner.

 

4.2

Development Plan. Licensee shall prepare a plan for the development of the Licensed Compounds (the “Development Plan”). The initial Development Plan is attached to this Agreement as Schedule 4.2.

 

4.3

Diligence. Licensee shall use Commercially Reasonable Efforts to develop the Licensed Compounds and the Licensed Products in the Field, and to obtain and maintain Regulatory Approvals for the Licensed Compounds and the Licensed Products in the Field in the Major Markets. Licensee shall allocate sufficient time, effort, equipment, and skilled personnel to complete its activities in accordance with each Development Plan and the timelines set forth therein.

 

4.4

Development Costs. Licensee shall be responsible for all costs and expenses in connection with the Development of, and obtaining and maintaining Regulatory Approvals for, the Licensed Products for use in the Field in the Territory.

 

 

4.5

Development Records.

 

4.5.1

Licensee shall, and shall cause its Affiliates and its and their Sublicensees to, maintain complete and accurate books and records relating to the development of the Licensed Compounds and the Licensed Products hereunder, in sufficient detail to verify compliance with the obligations under this Agreement. Such books and records shall (a) be appropriate for patent and regulatory purposes, (b) be in compliance with Applicable Law, (c) properly reflect all work done and results achieved in the performance of all development activities hereunder, (d) record only such activities and not include or be commingled with records of activities outside the scope of this Agreement and (e) be retained by Licensee for at least three (3) years after the expiration or termination of this Agreement in its entirety or for such longer period as may be required by Applicable Law. AstraZeneca shall have the right, during normal business hours and upon reasonable notice, to inspect and copy the books and records maintained by the Licensee and its Affiliates including, for clarity, any books and records of development provided to Licensee by any Sublicensee pursuant to this Section 4.4; provided that AstraZeneca shall maintain such records and information disclosed therein in confidence in accordance with Article 7.

 

4.5.2

Without limiting Section 4.5.1, within thirty (30) days (or seventy-five (75) days for activities conducted by a Sublicensee) following the end of each Calendar Year during which Licensee, its Affiliate, or its or their Sublicensees, are conducting development activities hereunder, Licensee shall provide AstraZeneca with a detailed written report of: (i) all development activities performed since the preceding report (or the Effective Date, with respect to the first report); (ii) all development activities in process; and (iii) the future activities it expects to initiate during the following twelve (12) month period. Each report shall contain sufficient detail to enable AstraZeneca to assess Licensee’s compliance with its obligations set forth in Section 4.3.1, including: (a) Licensee’s, or its Affiliates’ or its or their Sublicensees’ activities with respect to achieving Regulatory Approvals of Licensed Products in the Territory and (b) clinical study results and results of other development activities.

 

4.6

Regulatory Activities. Except as otherwise set forth in this Section 4.5, Licensee shall have the sole right to prepare, obtain and maintain Drug Approval Applications (including the setting of the overall regulatory strategy therefor), other Regulatory Approvals and other submissions (including INDs) and to conduct communications with the Regulatory Authorities, for the Licensed Compounds and the Licensed Products in the Field in the Territory.

 

 

4.7

Recalls, Suspensions or Withdrawals. As between the Parties, Licensee shall be solely responsible for handling any recall, market suspension or market withdrawal of the Licensed Compound or the Licensed Product in the Field in the Territory at its sole cost and expense; provided that prior to any implementation of a recall, market suspension or market withdrawal, Licensee shall consult with AstraZeneca and shall consider AstraZeneca’s comments in good faith. If a recall, market suspension or market withdrawal is mandated by a Regulatory Authority in the Territory, as between the Parties, Licensee shall initiate such a recall, market suspension or market withdrawal in compliance with Applicable Law.

 

4.8

Global Safety Database. Licensee shall establish, hold and maintain (at Licensee’s sole cost and expense) the global safety database for the Licensed Product.

 

4.9

Commercialization.

 

4.9.1

In General. Subject to AstraZeneca’s rights under Article 3, and the other terms and conditions of this Agreement, Licensee shall have the right and the obligation to commercialize the Licensed Products in the Field in the Territory at its sole cost and expense.

 

4.9.2

Diligence. Licensee shall use Commercially Reasonable Efforts to commercialize the Licensed Products throughout the Major Markets.

 

4.9.3

Booking of Sales; Distribution. Licensee shall invoice and book sales, establish all terms of sale (including pricing and discounts) and warehouse and distribute the Licensed Products in the Field in the Territory and perform or cause to be performed all related services. Licensee shall handle all returns, recalls or withdrawals (in accordance with Section 4.7), order processing, invoicing, collection, distribution and inventory management with respect to the Licensed Products in the Territory.

 

4.9.4

Commercialization Records. Without limitation of Section 5.6. Licensee shall maintain complete and accurate books and records pertaining to commercialization of the Licensed Products hereunder, in sufficient detail to verify compliance with its obligations under this Agreement and which shall be in compliance with Applicable Law and properly reflect all work done and results achieved in the performance of its commercialization activities. Such records shall be retained by Licensee for at least three (3) years after the expiration or termination of this Agreement in its entirety or for such longer period as may be required by Applicable Law. AstraZeneca shall have the right, during normal business hours and upon reasonable notice, to inspect and copy all such books and records maintained pursuant to this Section 4.9.4; provided that AstraZeneca shall maintain such records and information disclosed therein in confidence accordance with Article 7.

 

 

4.9.5

Commercialization Reports. Without limiting Section 4.9.4, within thirty (30) days following the end of each Calendar Year during which Licensee is conducting commercialization activities hereunder, Licensee shall provide AstraZeneca with detailed written reports of the commercialization activities it has performed, or caused to be performed, since the preceding report (or the Effective Date, with respect to the first report) and the future activities it expects to initiate during the following twelve (12) month period. Each report shall contain sufficient detail to enable AstraZeneca to assess Licensee’s compliance with its obligations set forth in Section 4.9.2.

 

4.10

Compliance with Applicable Law. Licensee shall, and shall cause its Affiliates and any permitted Sublicensees to, comply with all Applicable Law with respect to the Exploitation of Licensed Products.

 

4.11

Transfer of Inventory.

 

4.11.1

AstraZeneca hereby agrees to transfer to Licensee all or a portion of (at Licensee’s sole election) the quantities of existing inventory of Licensed Compounds or Licensed Products set out in Schedule 4.11, in the forms, in the maximum number of shipments and at the prices set forth therein (the “Inventory”). AstraZeneca’s obligation to transfer the Inventory (or a portion thereof) to Licensee, shall be subject to AstraZeneca having received, within the relevant timeline therefore specified in Schedule 4.11, a written request for such transfer from Licensee (each, an “Inventory Request”). Each Inventory Request must specify the quantity of the relevant Inventory that Licensee wishes to acquire (up to – but not in excess of – the quantities specified in Schedule 4.11) (in each case, the “Requested Inventory”). As soon as reasonably practicable following its receipt of the relevant Inventory Request, AstraZeneca shall issue an invoice for the Requested Inventory at the price set forth in Schedule 4.11, such invoice to be paid by Licensee no later than thirty (30) days from the date of the invoice. AstraZeneca shall within thirty (30) days following AstraZeneca’s receipt of the price for the Requested Inventory, deliver or have delivered the Requested Inventory to Licensee EXW (Incoterms 2020) the facility designated by AstraZeneca in the United Kingdom or Sweden (depending on current location as indicated in Schedule 4.11).

 

 

4.11.2

Licensee shall use the Requested Inventory delivered to it solely for the development of Licensed Compounds and Licensed Products pursuant to this Agreement.

 

4.11.3

AstraZeneca warrants and covenants that all Inventory provided to Licensee under Section 4.11.1: (a) was manufactured in accordance with AstraZeneca’s specifications, all Applicable Laws and cGMP; and (b) has been stored and maintained by AstraZeneca prior to delivery to Licensee (or its designee) (or such earlier date when the relevant Inventory is held by or on behalf of AstraZeneca ready for Licensee’s collection, regardless of the date of actual collection) in accordance with AstraZeneca’s standard procedures.

 

4.11.4

EXCEPT TO THE EXTENT SET FORTH IN SECTION 4.11.3 LICENSEE AGREES THAT ALL INVENTORY TRANSFERRED HEREUNDER IS PROVIDED “AS IS” AND WITHOUT ANY WARRANTIES, EXPRESS OR IMPLIED.

 

4.11.5

For the avoidance of doubt, it is acknowledged and agreed that – apart from the obligation to transfer the Requested Inventory in accordance with the provisions set out above in this Section 4.11 – AstraZeneca is under no obligation to Manufacture, have Manufactured, supply or have supplied any Licensed Compound or Licensed Product to Licensee under this Agreement and, as between the Parties, Licensee shall have the sole responsibility for, at its sole cost and expense, Manufacturing (or having Manufactured) and supplying Licensed Product for its, its Affiliates’ and Sublicensees’ Exploitation thereof.

 

4.12

Subcontracting. Subject to Section 2.2, either Party may subcontract with a Third Party to perform any or all of its obligations hereunder (including by appointing one or more distributors); provided that (a) no such permitted subcontracting shall relieve such Party of any obligation (except to the extent satisfactorily performed by such subcontractor) or any liability hereunder and such Party shall be and remain fully responsible and liable therefor and (b) the agreement pursuant to which such Party engages any Third Party subcontractor must (i) be consistent in all material respects with this Agreement, (ii) contain terms obligating such subcontractor to comply with the confidentiality, intellectual property and all other relevant provisions of this Agreement and (iii) contain terms obligating such subcontractor to permit such other Party rights of inspection, access and audit substantially similar to those provided to such other Party in this Agreement. Such Party shall ensure that each subcontractor accepts and complies with all of the applicable terms and conditions of this Agreement as if such permitted subcontractor were a party to this Agreement.

 

 

5.	PAYMENTS AND RECORDS

 

5.1

Consideration.

 

5.1.1

Upfront Payment. In partial consideration of the rights and licenses granted by AstraZeneca to Licensee under this Agreement, Licensee shall pay to AstraZeneca a non-creditable and non-refundable payment of $1,500,000 (one million five hundred thousand Dollars) (the “Upfront Payment”) within fourteen (14) days of receipt of an invoice from AstraZeneca for the same, such invoice to be issued on or following the Effective Date.

 

5.1.2

Share of Sublicense Revenue.

 

(a)

Sublicense Revenue. As further partial consideration of the rights and licenses granted by AstraZeneca to Licensee under this Agreement,

 

(i)

Licensee shall pay to AstraZeneca [***] payable to Licensee or its Affiliates that [***]. For clarity, AstraZeneca [***].

 

(ii)

In addition to any amounts payable under Section 5.1.2(a)(i), on [***].

 

(iii)

Amounts payable under this Section 5.1.2 shall be paid in accordance with Section 5.1.2(b).

 

 

(b)

Sublicense Revenue Reporting and Invoicing. Licensee shall procure that all Sublicensee(s) provide Licensee with [***].

 

5.1.3

Equity Issuance. As further, partial consideration for AstraZeneca’s grant of rights and licenses to Licensee under this Agreement, AstraZeneca shall receive from Licensee common stock in Licensee, in accordance with the terms and conditions of a certain Stock Issuance Agreement to be entered into between Licensee and AstraZeneca on or about the Effective Date in the form set out in Schedule 5.1.3.

 

5.2

Mode of Payment. All payments to AstraZeneca under this Agreement shall be made by deposit of Dollars in the requisite amount to such bank account as AstraZeneca may from time to time designate by notice to Licensee. For the purpose of calculating any sums due under this Agreement, Licensee shall convert any amount expressed in a foreign currency into Dollars equivalents using its, its Affiliate’s or Sublicensee’s, as applicable, standard conversion methodology consistent with IFRS or US Generally Accepted Accounting Practices.

 

5.3

Default Interest. If any payment due to AstraZeneca under this Agreement is not paid when due, then AstraZeneca shall be entitled to charge interest thereon [***]. Any interest will accrue from day to day and is calculated based on the actual number of days elapsed from the payment due date to the actual payment date and a year of three hundred and sixty-five (365) days. [***].

 

5.4

Licensee Exploitation of Licensed Products. If Licensee intends to [***].

 

 

5.5

Taxes.

 

5.5.1

General. The amounts payable by Licensee to AstraZeneca pursuant to this Agreement (each, a “Payment”) shall be paid free and clear of any and all taxes, except for any withholding taxes required by Applicable Law. Except as provided in this Section 5.5, AstraZeneca shall be solely responsible for paying any and all Taxes (other than withholding taxes required by Applicable Law to be deducted from Payments and remitted by Licensee) levied on account of, or measured in whole or in part by reference to, any Payments it receives. Licensee shall deduct or withhold from the Payments any Taxes that it is required by Applicable Law to deduct or withhold. Notwithstanding the foregoing, if AstraZeneca is entitled under any applicable Tax treaty to a reduction of rate of, or the elimination of, applicable withholding tax, it may deliver to Licensee or the appropriate Governmental Authority (with the assistance of Licensee to the extent that this is reasonably required and is requested in writing) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve Licensee of its obligation to withhold such Tax and Licensee shall apply the reduced rate of withholding or dispense with withholding, as the case may be; provided that Licensee has received evidence of AstraZeneca’s delivery of all applicable forms (and, if necessary, its receipt of appropriate governmental authorization) at least fifteen (15) days prior to the time the Payments are due. If, in accordance with the foregoing, Licensee withholds any amount, it shall pay to AstraZeneca the balance when due, make timely payment to the proper taxing authority of the withheld amount and send to AstraZeneca proof of such payment within ten (10) days following such payment.

 

5.5.2

VAT. Notwithstanding anything contained in Section 5.5.1, this Section 5.5.2 shall apply with respect to VAT. All Payments are exclusive of VAT. If any VAT is chargeable in respect of any Payments, Licensee shall pay VAT at the applicable rate in respect of any such Payments following the receipt of a VAT invoice in the appropriate form issued by AstraZeneca in respect of those Payments, such VAT to be payable on the later of the due date of the payment of the Payments to which such VAT relates and thirty (30) days after the receipt by Licensee of the applicable invoice relating to that VAT payment. The Parties will issue invoices for all amounts due under this Agreement consistent with indirect tax requirements.

 

 

5.5.3

Gross Up. If either Party assigns this Agreement to an Affiliate or to a Third Party and, as a result of such assignment, Payments made hereunder are subject to additional withholding tax, the assigning Party shall be responsible for the resulting additional withholding taxes. If the non-assigning Party receives a Tax benefit as a result of the assignment, the non- assigning Party shall reimburse the assigning Party for the appropriate amount of any Tax benefit it has received (including through the use of foreign tax credit); provided that the non-assigning Party shall take all commercially reasonable actions necessary to obtain any available Tax benefit with respect to such additional withholding taxes and to defend such benefit in a Tax audit.

 

5.6

Financial Records. Licensee shall, and shall cause its Affiliates and its and their Sublicensees to, keep complete and accurate financial books and records pertaining to the commercialization of Licensed Products hereunder, including any and all Sublicense Revenue, in sufficient detail to calculate and verify all amounts payable hereunder. Licensee shall, and shall cause its Affiliates and its and their Sublicensees to, retain such books and records until the latest of (a) three (3) years after the end of the period to which such books and records pertain, (b) the expiration of the applicable Tax statute of limitations (or any extensions thereof) and (c) for such period as may be required by Applicable Law.

 

5.7

Audit. At AstraZeneca’s request, Licensee shall, and shall cause its Affiliates and its and their Sublicensees to, permit AstraZeneca or an independent auditor designated by AstraZeneca and reasonably acceptable to Licensee, at reasonable times and upon reasonable notice, to audit the books and records maintained pursuant to Section 5.6 to ensure the accuracy of all reports and payments made hereunder. The cost of any audit shall be borne by AstraZeneca, unless an audit reveals, with respect to a period, a variance of more than five percent (5%) from the reported amounts for such period, in which case Licensee shall bear the cost of such audit. Unless disputed pursuant to Section 5.8, if an audit concludes that (a) additional amounts were owed by Licensee, Licensee shall pay the additional amounts, with interest from the date originally due as provided in Section 5.3 or (b) excess payments were made by Licensee, AstraZeneca shall reimburse such excess payments, in either case ((a) or (b)), within sixty (60) days after the date on which such audit is completed by or on behalf of AstraZeneca.

 

 

5.8

Audit Dispute. In the event of a dispute with respect to any audit under Section 5.7, AstraZeneca and Licensee shall work in good faith to resolve the disagreement. If the Parties are unable to reach a mutually acceptable resolution of any such dispute within thirty (30) days, the dispute shall be submitted for resolution to a certified public accounting firm jointly selected by each Party’s certified public accountants or to such other Person as the Parties shall mutually agree (the “Auditor”). The decision of the Auditor shall be final and the costs of such arbitration as well as the initial audit shall be borne between the Parties in such manner as the Auditor shall determine. Not later than ten (10) days after such decision and in accordance with such decision, Licensee shall pay the additional amounts, with interest from the date originally due as provided in Section5.3, or AstraZeneca shall reimburse the excess payments, as applicable.

 

5.9

Anti-Tax Evasion.

 

5.9.1

Each of AstraZeneca and Licensee represents, warrants and undertakes that neither it nor its Affiliates shall commit a UK tax evasion facilitation offence under section 45(5) of the UK Criminal Finances Act 2017 in connection with or attributable to this Agreement or the transactions contemplated hereby.

 

5.9.2

Each Party shall promptly report to the other Party any apparent breach of Section 5.9.1 and shall (i) answer, in reasonable detail, any written or oral inquiry from the other Party related to its and its Affiliates compliance with Section 5.9.1, (ii) facilitate the interview of employees of such Party by the other Party (or any agent of such Party) at any reasonable time specified by the inquiring Party related to such Party’s compliance with Section 5.9.1, and (iii) co-operate with the inquiring Party and/or any Governmental Authority in relation to any investigation relating to the matters referred to in Section 5.9.1, in all cases, as reasonably required to enable that other Party to comply with its undertaking in Section 5.9.1.

 

6.	INTELLECTUAL PROPERTY

 

6.1

Ownership of Intellectual Property.

 

6.1.1

Ownership of Technology. Subject to Section 6.1.2, as between the Parties, each Party shall own and retain all right, title and interest in and to any and all: (a) Information and inventions that are conceived, discovered, developed or otherwise made solely by or on behalf of such Party or its Affiliates or its or their respective (sub)licensees (or Sublicensee(s)), as applicable, under or in connection with this Agreement, whether or not patented or patentable and any and all Patents and other intellectual property rights with respect thereto; and (b) other Information, inventions, Patents and other intellectual property rights that are owned or otherwise Controlled (other than pursuant to the license grants set forth in Section 2.1) by such Party or its Affiliates or its or their (sub)licensees (or Sublicensees) (as applicable) outside of this Agreement.

 

 

6.1.2

Ownership of Joint Patents and Joint Know-How. Each of AstraZeneca and Licensee shall own an equal, undivided interest in any and all: (a) Information and inventions that are conceived, discovered, developed or otherwise made jointly by or on behalf of AstraZeneca or its Affiliates or its or their (sub)licensees, on the one hand, and Licensee or its Affiliates or its or their Sublicensees, on the other hand, under or in connection with this Agreement, whether or not patented or patentable (the “Joint Know-How”); and (b) Patents (the “Joint Patents”) and other intellectual property rights with respect to the Information and inventions described in clause (a) (together with Joint Know-How and Joint Patents, the “Joint Intellectual Property Rights”). Each Party shall promptly disclose to the other Party in writing and shall cause its Affiliates and its and their (sub)licensees (or Sublicensees) to so disclose, the development, making, conception or reduction to practice of any Joint Know-How or Joint Patents. Subject to the licenses and rights of reference granted under Section 2.1, each Party shall have the right to Exploit the Joint Intellectual Property Rights without a duty of seeking consent or accounting to the other Party. If in a particular country the consent of co-owners is required for one co-owner to grant license rights under or otherwise exploit any Joint Patent as provided in the previous sentence, subject to Section 2.1, (i) each Party hereby consents to such license grant to use and otherwise Exploit such Joint Patent in such country without any duty to share profits with, or provide an accounting to, such Party with respect to such use and Exploitation, and (ii) each Party hereby grants to the other Party a perpetual, irrevocable, royalty-free, sub-licensable, non- exclusive license under such granting Party’s interest in such Joint Patent(s) to Exploit any Joint Patent or Joint Know-How in such country in any manner and for any purpose whatsoever.

 

6.1.3

Assignment Obligation. Each Party shall, and does hereby, assign, and shall cause its Affiliates and its and their respective (sub)licensees and Sublicensees to so assign, to the other Party, without additional compensation, such right, title and interest in and to any Information and inventions as well as any intellectual property rights with respect thereto, as is necessary to fully effect, as applicable, the provisions of this Section 6.1 (Ownership of Intellectual Property), to the extent required and not already effected by operation of law. Each Party shall cause all Persons who perform development activities or regulatory activities for such Party under this Agreement or who conceive, discover, develop or otherwise make any Information or inventions by or on behalf of such Party or its Affiliates or its or their respective (sub)licensees (or Sublicensees) under or in connection with this Agreement to be under an obligation to assign their rights in any Information and inventions resulting therefrom to such Party, except where Applicable Law requires otherwise and except in the case of governmental, not-for-profit and public institutions that have standard policies against such an assignment (in which case, a suitable license or right to obtain such a license, shall be obtained).

 

 

6.2

Maintenance and Prosecution of Patents.

 

6.2.1

In General. As between the Parties, (a) AstraZeneca shall have the first right, but not the obligation, to prepare, file, prosecute and maintain the AstraZeneca Patents, (b) Licensee shall have the first right, but not the obligation, to prepare, file, prosecute and maintain the Joint Patents, and (c) Licensee shall have the sole right, but not the obligation, to prepare, file, prosecute and maintain the Licensee Patents, in each case ((a), (b) and (c), including any related interference, re-issuance, re-examination and opposition proceedings with respect thereto, in the Territory at its sole cost and expense and through counsel of its choice. If, as between the Parties, the Party with the first right to prosecute or maintain an AstraZeneca Patent or a Joint Patent decides not to prepare, file, prosecute or maintain such AstraZeneca Patent or Joint Patent in a country in the Territory, such Party shall provide reasonable prior written notice to the other Party of such intention and the other Party shall thereupon have the right, subject to the prior written consent of the first Party (which consent shall not be unreasonably withheld, conditioned or delayed), to assume the control and direction of the preparation, filing, prosecution and maintenance of such AstraZeneca Patent or Joint Patent at its sole cost and expense in such country.

 

6.2.2

Cooperation. Each Party shall, and shall cause its Affiliates to, assist the other Party at the reasonable request of the other Party from time to time in connection with its activities set forth in Section 6.2.1. The Party that has the right to prepare, file, prosecute and maintain the AstraZeneca Patents or the Joint Patents, as applicable (the “Prosecuting Party”) shall (a) keep the other Party (the “Non-Prosecuting Party”) informed of all steps to be taken in the preparation and prosecution of all applications filed by it pursuant to Section 6.2.1, (b) furnish the Non-Prosecuting Party with copies of such applications for Patents, amendments thereto and other related correspondence to and from patent offices, including correspondence relating to any office actions, and (c) to the extent reasonably practicable, permit the Non-Prosecuting Party an opportunity to offer its comments on such applications, amendments and other correspondence before making a submission to a patent office, which comments Prosecuting Party shall consider in good faith. The Non-Prosecuting Party shall offer its comments, if any, promptly.

 

 

6.2.3

Patent Term Extension and Supplementary Protection Certificate. As between the Parties, Licensee shall have the sole right to apply for patent term extensions, in the Territory, including the United States with respect to extensions pursuant to 35 U.S.C. §156 et seq. and in other jurisdictions pursuant to supplementary protection certificates, and in all jurisdictions with respect to any other extensions that are now or become available in the future, wherever applicable, for the AstraZeneca Patents, Joint Patents or Licensee Patents and with respect to the Licensed Compounds and the Licensed Products, in each case including whether or not to do so. AstraZeneca shall provide prompt and reasonable assistance, as requested by Licensee, including by taking such action as patent holder as is required under any Applicable Law to obtain such extension or supplementary protection certificate.

 

6.3

Common Ownership Under Joint Research Agreements. Notwithstanding anything to the contrary in this Article 6, neither Party shall have the right to make an election under 35 U.S.C. 102(c) when exercising its rights under this Article 6 without the prior written consent of the other Party. With respect to any such permitted election, the Parties shall coordinate their activities with respect to any submissions, filings or other activities in support thereof. The Parties acknowledge and agree that this Agreement is a “joint research agreement” as defined in 35 U.S.C. 100(h).

 

6.4

Patent Listings. As between the Parties, Licensee shall have the sole right to make decisions regarding and Licensee shall have the right to make all filings with Regulatory Authorities in the Territory with respect to the AstraZeneca Patents, Joint Patents or Licensee Patents, in each case solely related to the Exploitation by Licensee, its Affiliate, or any Sublicensee, of any Licensed Product in the Territory in the Field, including as required or allowed (a) in the United States, in the FDA’s Orange Book and (b) in the European Union, under the national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83 or other international equivalents.

 

6.5

Enforcement of Patents.

 

6.5.1

Notice. Each Party shall promptly notify the other Party in writing of any alleged or threatened infringement of the AstraZeneca Patents, Joint Patents or Licensee Patents in any jurisdiction in the Territory of which such Party becomes aware in connection with the Exploitation of any Licensed Product or any product that competes with a Licensed Product (an “Infringement”).

 

 

6.5.2

Enforcement of Patents. As between the Parties Licensee shall have (a) the first right, but not the obligation, to prosecute any Infringement with respect to the AstraZeneca Patents and Joint Patents, and (b) the sole right, but not the obligation, to prosecute any Infringement with respect to the Licensee Patents, in each case ((a) or (b)) including as a defense or counterclaim in connection with any Third Party Infringement Claim, at Licensee’s sole cost and expense; provided that if Licensee does not take commercially reasonable steps to prosecute such an Infringement with respect to an AstraZeneca Patent or Joint Patent (i) within ninety (90) days following the first notice provided above with respect to such Infringement or (ii) provided such date occurs after the first such notice of such Infringement is provided, thirty (10) Business Days before the time limit, if any, set forth in appropriate laws and regulations for filing of such actions, whichever comes first, then Licensee shall so notify AstraZeneca and AstraZeneca may prosecute such Infringement at its sole cost and expense.

 

6.5.3

Cooperation. If a Party is entitled to, and pursues an action against an Infringement in accordance with Section 6.5.2 the other Party shall, and shall cause its Affiliates to, cooperate fully, including being joined as a necessary party to such action, providing access to relevant documents and other evidence and making its employees available at reasonable business hours, (b) the Party pursuing any action against an Infringement shall consult with the other Party as to the strategy for such action and (c) such Party shall consider in good faith any comments from the other Party and shall keep the other Party reasonably informed of any steps taken with respect to such action.

 

6.5.4

Settlement. The Party that is entitled to and pursues an action against an Infringement in accordance with this Section 6.5 shall have the right to control any settlement of such claim; provided that no settlement shall be entered into without the prior consent of the other Party (which consent shall not be unreasonably withheld, conditioned or delayed) if such settlement would reasonably be expected to have a material adverse effect on the rights or interest of the other Party or any of its Affiliates or impose any costs or liability on or involve any admission by, the other Party or any of its Affiliates.

 

 

6.5.5

Cost Recovery. Each Party shall bear its own costs and expenses relating to any Infringement action commenced pursuant to this Section 6.5; provided that the pursuing Party shall reimburse the other Party for the costs and expenses incurred by the other Party for any assistance requested by the pursuing Party for such Infringement action. Except as otherwise agreed by the Parties in connection with a cost sharing arrangement, any recovery realized as a result of such litigation described above in this Section 6.5 (whether by way of settlement or otherwise) shall be first, allocated to reimburse the Parties for their costs and expenses in making such recovery (which amounts shall be allocated pro rata if insufficient to cover the totality of such expenses). Any remainder after such reimbursement is made shall be retained by the pursuing Party; provided, however, that to the extent that any award or settlement (whether by judgment or otherwise) with respect to an AstraZeneca Patent, Joint Patent or Licensee Patent is attributable to loss of sales or profits with respect to a Licensed Product, the Parties shall negotiate in good faith an appropriate allocation of such remainder to reflect the economic interests of the Parties under this Agreement with respect to such Licensed Product.

 

6.6

Infringement Claims by Third Parties. If the Exploitation of a Licensed Product in the Territory pursuant to this Agreement results in, or is reasonably expected to result in, any claim, suit or proceeding by a Third Party alleging infringement by Licensee or any of its Affiliates or its or their Sublicensees, distributors or customers (a “Third Party Infringement Claim”), including any defense or counterclaim in connection with an Infringement action initiated pursuant to Section 6.5, the Party first becoming aware of such Third Party Infringement Claim shall promptly notify the other Party in writing. As between the Parties, Licensee shall be responsible for defending any such Third Party Infringement Claim at its sole cost and expense, using counsel of Licensee’s choice. AstraZeneca may participate in any such claim, suit or proceeding with counsel of its choice at its sole cost and expense; provided that Licensee shall retain the right to control such claim, suit or proceeding. AstraZeneca shall, and shall cause its Affiliates to, assist and cooperate with Licensee, as Licensee may reasonably request from time to time, in connection with its activities set forth in this Section 6.6, including where necessary, furnishing a power of attorney solely for such purpose or joining in, or being named as a necessary party to, such action, providing access to relevant documents and other evidence and making its employees available at reasonable business hours; provided that Licensee shall reimburse AstraZeneca for its reasonable and verifiable out-of-pocket costs and expenses incurred in connection therewith. Licensee shall keep AstraZeneca reasonably informed of all material developments in connection with any such claim, suit or proceeding. Licensee agrees to provide AstraZeneca with copies of all material pleadings filed in such action and to allow AstraZeneca reasonable opportunity to participate in the defense of the claims. Any damages, or awards, including royalties incurred or awarded in connection with any Third Party Infringement Claim defended under this Section 6.6 shall be borne by Licensee provided that to the extent such damages or awards relate to the Exploitation of a Licensed Compound, such amounts may be credited against any amounts payable by Licensee to AstraZeneca pursuant to Section 5.1.2.

 

 

6.7

Invalidity or Unenforceability Defenses or Actions. Each Party shall promptly notify the other Party in writing of any alleged or threatened assertion of invalidity or unenforceability of any of the AstraZeneca Patents, Joint Patents or Licensee Patents by a Third Party of which such Party becomes aware. As between the Parties Licensee shall have (a) the first right, but not the obligation, to defend and control the defense of the validity and enforceability of the AstraZeneca Patents and the Joint Patents and (b) the sole right, but not the obligation, to defend and control the defense of the validity and enforceability of the Licensee Patents, in each case ((a) or (b)) at its sole cost and expense, using counsel of Licensee’s choice, including, when such invalidity or unenforceability is raised as a defense or counterclaim in connection with an Infringement action initiated pursuant to Section 6.5. With respect to any such claim, suit or proceeding in the Territory referred to in clause (a), AstraZeneca may participate in such claim, suit or proceeding with counsel of its choice at its sole cost and expense; provided that Licensee shall retain control of the defense in such claim, suit or proceeding. If Licensee or its designee elects not to defend or control the defense of the applicable AstraZeneca Patents or Joint Patents in a suit brought in the Territory or otherwise fails to initiate and maintain the defense of any such claim, suit or proceeding, then AstraZeneca may conduct and control the defense of any such claim, suit or proceeding at its sole cost and expense. If and to the extent necessary, AstraZeneca shall, and shall cause its Affiliates to, cooperate fully, including being joined as a party plaintiff in such action, providing access to relevant documents and other evidence and making its employees available at reasonable business hours; provided that, except with respect to Joint Patents, Licensee shall reimburse AstraZeneca for its reasonable and verifiable out-of-pocket costs and expenses incurred in connection therewith. Licensee shall consider in good faith any comments from AstraZeneca and shall keep AstraZeneca reasonably informed of any steps taken with respect to such action.

 

6.8

UPC. With respect to the AstraZeneca Patents, the Joint Patents or the Licensee Patents, the Prosecuting Party will have the sole right to determine whether to opt in or opt out (and to opt in again) of the Unified Patent Court system. With respect to the AstraZeneca Patents or the Joint Patents, (a) the Prosecuting Party shall (i) inform the Non-Prosecuting Party of their intended decision regarding opt out or opt in, and (ii) to the extent reasonably practicable, permit the Non-Prosecuting Party an opportunity to offer their comments on this decision, which comments Prosecuting Party shall consider in good faith, and (b) the Non-Prosecuting Party shall offer its comments, if any, promptly. Each Party will, to the extent necessary and applicable, take such actions as required to effect the opt out or withdrawal of the opt out, as soon as reasonably practicable.

 

 

6.9

Product Trademarks.

 

6.9.1

Ownership of Product Trademarks. As between the Parties, Licensee shall own all right, title and interest to the Product Trademarks in the Territory.

 

6.9.2

Prosecution of Product Trademarks. Licensee shall be responsible for the registration, prosecution and maintenance of the Product Trademarks using counsel of its own choice. All costs and expenses of registering, prosecuting, and maintaining the Product Trademarks shall be borne solely by Licensee.

 

6.9.3

Selection of Product Trademarks. Licensee shall not and shall not permit its Affiliates or Sublicensees to use in their respective businesses any Trademark that (a) contains any term in any Trademark used by AstraZeneca or its Affiliates, or its and their (sub)licensees, unless otherwise agreed to by AstraZeneca in writing, or (b) is confusingly similar to, or a colourable imitation of, any Trademark used by AstraZeneca or its Affiliates, or its and their (sub)licensees.

 

7.	CONFIDENTIALITY AND NON-DISCLOSURE

 

7.1

Confidentiality Obligations. At all times during the Term and for a period of ten (10) years following termination or expiration of this Agreement in its entirety, each Party shall, and shall cause its officers, directors, employees and agents to, keep confidential and not publish or otherwise disclose to a Third Party and not use, directly or indirectly, for any purpose, any Confidential Information of the other Party, except to the extent such disclosure or use is expressly permitted by the terms of this Agreement. “Confidential Information” means any technical, business or other information provided by or on behalf of one Party (the “Disclosing Party”) to the other Party (the “Receiving Party”) in connection with this Agreement, whether prior to, on or after the Effective Date, including information relating to the terms of this Agreement (subject to Section 7.4), information relating to the Licensed Compounds or any Licensed Product (including the Regulatory Documentation) or any development or commercialization of the Licensed Compounds or any Licensed Product, any know-how with respect thereto developed by or on behalf of the Disclosing Party or its Affiliates (including Licensee Know-How and AstraZeneca Know-How, as applicable) or the scientific, regulatory or business affairs or other activities of either Party. Notwithstanding the foregoing, Joint Know- How and the terms of this Agreement shall be deemed to be the Confidential Information of both Parties and each Party shall be deemed to be the Receiving Party and the Disclosing Party with respect thereto. Notwithstanding the foregoing, the confidentiality and non-use obligations under this Section 7.1 with respect to any Confidential Information shall not apply to any information that:

 

7.1.1

is or hereafter becomes part of the public domain by public use, publication, general knowledge or the like through no breach of this Agreement by the Receiving Party;

 

 

7.1.2

can be demonstrated by documentation or other competent proof to have been in the Receiving Party’s possession prior to disclosure by the Disclosing Party without any obligation of confidentiality with respect to such information; provided that the foregoing exception shall not apply with respect to Joint Know-How;

 

7.1.3

is subsequently received by the Receiving Party from a Third Party who is not bound by any obligation of confidentiality with respect to such information; or

 

7.1.4

can be demonstrated by documentation or other competent evidence to have been independently developed by or for the Receiving Party without reference to the Disclosing Party’s Confidential Information; provided that the foregoing exception shall not apply with respect to Joint Know-How.

 

Specific aspects or details of Confidential Information shall not be deemed to be within the public domain or in the possession of the Receiving Party merely because the Confidential Information is embraced by more general information in the public domain or in the possession of the Receiving Party. Further, any combination of Confidential Information shall not be considered in the public domain or in the possession of the Receiving Party merely because individual elements of such Confidential Information are in the public domain or in the possession of the Receiving Party unless the combination and its principles are in the public domain or in the possession of the Receiving Party.

 

7.2

Permitted Disclosures. Each Party (as Receiving Party) may disclose Confidential Information of the other Party as expressly permitted by this Agreement or if and to the extent such disclosure is reasonably necessary in the following instances:

 

7.2.1

disclosure to Third Parties in connection with due diligence or similar investigations, and disclosure to potential Third Party investors in confidential financing documents, provided, in each case, that any such Third Party agrees to be bound by written confidentiality and non-use obligations with respect to such information substantially similar to those set out in this Agreement provided that the duration of such obligations shall only be required to be three (3) years following disclosure of such information for such obligations to comply with the Receiving Party’s obligations under this Section 7.2.1;

 

 

7.2.2

disclosure to its or its Affiliates’ financial and legal advisors who have a need to know such Disclosing Party’s Confidential Information and are either under professional codes of conduct giving rise to obligations of confidentiality and non-use or under written confidentiality and non-use obligations with respect to such information substantially similar to those set out in this Agreement;

 

7.2.3

disclosure to actual or potential subcontractors as may be necessary or useful in connection with the performance of its obligations or exercise of its rights as contemplated by this Agreement, provided that such Persons shall be subject to written confidentiality and non-use obligations with respect to such information substantially similar to those set out in this Agreement provided that the duration of such obligations shall only be required to be five (5) years following disclosure of such information for such obligations to comply with the Receiving Party’s obligations under this Section 7.2.3;

 

7.2.4

disclosure to a Taxing Authority in connection with the Tax affairs or a reporting obligation of the Disclosing Party;

 

7.2.5

disclosure to actual or potential Sublicensees or other Third Parties as may be necessary or useful for the exercise of its rights under this Agreement, provided that such Persons shall be subject to written confidentiality and non-use obligations substantially similar to those set out in this Agreement provided that the duration of such obligations shall only be required to be five (5) years following disclosure of such information for such obligations to comply with the Receiving Party’s obligations under this Section 7.2.3; or

 

7.2.6

to the extent that such disclosure is made in response to a valid order of a court of competent jurisdiction or other supra-national, federal, national, regional, state, provincial and local governmental, Taxing Authority, or regulatory body of competent jurisdiction or, if in the reasonable opinion of the Receiving Party’s legal counsel, such disclosure is otherwise required to comply with Applicable Law or its or its Affiliates’ respective regulatory, or financing reporting requirements, including by reason of filing with securities regulators or the rules of a stock exchange on which the securities of the Receiving Party are listed (or to which an application for listing has been submitted); provided, however, that before any such disclosure, the Receiving Party shall first notify the Disclosing Party and provide the Disclosing Party a reasonable opportunity to quash such order or to obtain a protective order or confidential treatment requiring that the Confidential Information and documents that are the subject of such order be held in confidence by such court or agency or, if disclosed, be used only for the purposes for which the order was issued or such disclosure was required by Applicable Law; and provided, further, that the Confidential Information disclosed in response to such court or governmental order or Applicable Law shall be limited to that information which is legally required to be disclosed in response to such court or governmental order or by such Applicable Law.

 

 

7.3

Use of Name. Except as expressly provided herein, neither Party shall mention or otherwise use the Corporate Name, logo or Trademark of the other Party or any of its Affiliates or any of its or their (sub)licensees (or Sublicensees) (or any abbreviation or adaptation thereof) in any publication, press release, marketing, investment and promotional material or other form of publicity without the prior written approval of such other Party in each instance. The restrictions imposed by this Section 7.3 shall not prohibit (a) either Party from making any disclosure identifying the other Party to the extent required in connection with its exercise of its rights or obligations under this Agreement and (b) either Party from making any disclosure identifying the other Party that is required by Applicable Law or the rules of a stock exchange on which the securities of the disclosing Party are listed (or to which an application for listing has been submitted).

 

7.4

Public Announcements. The Parties have agreed that Licensee may within three Business Days following the License Effective Date issue a press release regarding this Agreement and its subject matter, which press release shall be in accordance with Schedule 7.4 (the “Agreed Press Release”). Other than the Agreed Press Release, neither Party shall issue any other public announcement, press release or other public disclosure regarding this Agreement or its subject matter without the other Party’s prior written consent, such consent not to be unreasonably withheld, delayed or conditioned, except for any such disclosure that is required by Applicable Law or the rules of a stock exchange on which the securities of the issuing Party are listed (or to which an application for listing has been submitted), provided that, to the extent practicable and permitted by Applicable Law and the rules of the relevant stock exchange, the issuing Party shall allow the other Party to review a close to final draft of such required disclosure and to make comments on such draft and the issuing Party shall take any reasonable comments provided by the other Party into account in good faith when making such required disclosure.

 

 

7.5

Return of Confidential Information. Upon the effective date of the expiration or termination of this Agreement for any reason, the Disclosing Party may request in writing and the Receiving Party shall either, with respect to Confidential Information of the Disclosing Party to which such Receiving Party does not retain rights under the surviving provisions of this Agreement, at the Disclosing Party’s election, (a) promptly destroy all copies of such Confidential Information in the possession or control of the Receiving Party and confirm such destruction in writing to the Disclosing Party or (b) promptly deliver to the Disclosing Party, at the Receiving Party’s sole cost and expense, all copies of such Confidential Information in the possession or control of the Receiving Party. Notwithstanding the foregoing, the Receiving Party shall be permitted to retain such Confidential Information (i) to the extent necessary or useful for purposes of performing any continuing obligations or exercising any ongoing rights hereunder and, in any event, a single copy of such Confidential Information for archival purposes and (ii) any computer records or files containing such Confidential Information that have been created solely by such Receiving Party’s automatic archiving and back-up procedures, to the extent created and retained in a manner consistent with such Receiving Party’s standard archiving and back-up procedures, but not for any other uses or purposes. All Confidential Information shall continue to be subject to the terms of this Agreement for the period set forth in Section 7.1.

 

8.	REPRESENTATIONS AND WARRANTIES

 

8.1

Mutual Representations and Warranties. Each Party represents and warrants to the other Party, as of the Effective Date, and covenants, that:

 

8.1.1

it is a legal entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization and has all requisite power and authority, corporate or otherwise, to execute, deliver and perform this Agreement;

 

8.1.2

the execution and delivery of this Agreement and the performance by it of the transactions contemplated hereby have been duly authorized by all necessary corporate action and do not violate: (a) such Party’s charter documents, bylaws or other organizational documents; (b) in any material respect, any agreement, instrument or contractual obligation to which such Party is bound (other than, as to AstraZeneca, the Earlier License Agreement); (c) any requirement of any Applicable Law; or (d) any order, writ, judgment, injunction, decree, determination or award of any court or governmental agency presently in effect applicable to such Party;

 

8.1.3

this Agreement is a legal, valid and binding obligation of such Party enforceable against it in accordance with its terms and conditions, subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance and general principles of equity (whether enforceability is considered a proceeding at law or equity);

 

 

8.1.4

it is not under any obligation, contractual or otherwise, to any Person that conflicts with or is inconsistent in any material respect with the terms of this Agreement or that would impede the diligent and complete fulfilment of its obligations hereunder (other than, as to AstraZeneca, the Earlier License Agreement); and

 

8.1.5

neither it nor any of its Affiliates has been debarred or is subject to debarment and neither it nor any of its Affiliates will use in any capacity, in connection with the services to be performed under this Agreement, any Person who has been debarred pursuant to Section 306 of the FFDCA or who is the subject of a conviction described in such section. It will inform the other Party in writing promptly if it or any such Person who is performing services hereunder is debarred or is the subject of a conviction described in Section 306 or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to the best of its or its Affiliates’ knowledge, is threatened, relating to the debarment or conviction of it or any such Person performing services hereunder.

 

8.2

Additional Representations of AstraZeneca. AstraZeneca further represents and warrants to Licensee, as of the Effective Date, that, subject to termination of the Earlier License Agreement:

 

8.2.1

AstraZeneca Controls the AstraZeneca Patents as of the Effective Date and has the right to grant the licenses specified herein; and

 

8.2.2

the AstraZeneca Patents are the only Patents Controlled by AstraZeneca as of the Effective Date that are necessary to Exploit the Licensed Compounds in the form as they exist as of the Effective Date.

 

8.3

Additional Representations and Warranties of Licensee. Licensee further represents and warrants to AstraZeneca, as of the Effective Date, that Licensee: (a) has conducted its own investigation and analysis of (i) the Patent and other proprietary rights of Third Parties as such rights relate to the Exploitation of the Licensed Compounds and Licensed Products and (ii) the potential infringement thereof; (b) understands the complexity and uncertainties associated with possible claims of infringement of Patent or other proprietary rights of Third Parties, particularly those relating to pharmaceutical products; and (c) acknowledges and agrees that it is solely responsible for the risks of such claims.

 

 

8.4

Disclaimer of Warranties. Except for the express warranties set forth herein, neither Party makes any representations or grants any warranties, express or implied, either in fact or by operation of law, by statute or otherwise and each Party specifically disclaims any other warranties, whether written or oral or express or implied, including any warranty of quality, merchantability or fitness for a particular use or purpose or any warranty as to the validity of any patents or the non-infringement of any intellectual property rights of Third Parties.

 

8.5

Additional waiver. Licensee agrees that except as expressly set forth in this Agreement: (a) the AstraZeneca Patents are licensed “as is,” “with all faults,” and “with all defects,” and Licensee expressly waives all rights to make any claim whatsoever against AstraZeneca for misrepresentation or for breach of promise, guarantee or warranty of any kind relating to the AstraZeneca Patents; (b) Licensee agrees that AstraZeneca will have no liability to Licensee for any act or omission in the preparation, filing, prosecution, maintenance, enforcement, defence or other handling of the AstraZeneca Patents; and (c) Licensee is solely responsible for determining whether the AstraZeneca Patents have applicability or utility in Licensee’s contemplated exploitation of the Licensed Products and Licensee assumes all risk and liability in connection with such determination.

 

8.6

Anti-Bribery and Anti-Corruption Compliance. Each Party agrees, on behalf of itself, its officers, directors and employees and on behalf of its Affiliates, agents, representatives, consultants and subcontractors hired in connection with the subject matter of this Agreement (“Representatives”) that for the performance of its obligations hereunder:

 

8.6.1

such Party and its Representatives shall comply with the Anti-Corruption Laws and shall not take any action that will, or would reasonably be expected to, cause the other Party or its Affiliates to be in violation of any Anti-Corruption Laws; and

 

8.6.2

such Party shall promptly provide the other Party with written notice upon becoming aware of any breach or violation by such Party or its Representative of any of the provisions contained in this Section 8.6.1.

 

9.

INDEMNITY

 

9.1

Indemnification of AstraZeneca. Licensee shall indemnify AstraZeneca, its Affiliates, and its and their respective directors, officers, employees and agents (the “AstraZeneca Indemnitees”) and defend and save each of them harmless, from and against any and all losses, damages, liabilities, costs and expenses (including reasonable attorneys’ fees and expenses) (collectively, “Losses”) in connection with any and all suits, investigations, claims or demands of Third Parties (collectively, “Third Party Claims”) arising from or occurring as a result of: (a) the breach by Licensee of this Agreement; (b) the gross negligence or willful misconduct on the part of Licensee or its Affiliates or its or their Sublicensees or its or their distributors or contractors or its or their respective directors, officers, employees or agents in performing its or their obligations under this Agreement; or (c) the Exploitation by or on behalf of Licensee or any of its Affiliates or its or their Sublicensees or its or their distributors or contractors of any Licensed Product or the Licensed Compounds in or for the Territory, except, in each case ((a), (b) and (c)), for those Losses for which AstraZeneca has an obligation to indemnify Licensee pursuant to Section 9.2, as to which Losses each Party shall indemnify the other to the extent of their respective liability.

 

 

9.2

Indemnification of Licensee. AstraZeneca shall indemnify Licensee, its Affiliates and their respective directors, officers, employees and agents (the “Licensee Indemnitees”) and defend and save each of them harmless, from and against any and all Losses in connection with any and all Third Party Claims arising from or occurring as a result of: (a) the breach by AstraZeneca of this Agreement; or (b) the gross negligence or willful misconduct on the part of AstraZeneca or its Affiliates or its or their respective directors, officers, employees or agents in performing its obligations under this Agreement, except, in each case ((a) and(b)), for those Losses for which Licensee has an obligation to indemnify AstraZeneca pursuant to Section 9.1, as to which Losses each Party shall indemnify the other to the extent of their respective liability for the Losses.

 

9.3

Indemnification Procedures. All indemnification claims in respect of an AstraZeneca Indemnitee or Licensee Indemnitee shall be made solely by AstraZeneca or Licensee, as applicable (each of AstraZeneca or Licensee in such capacity, the “Indemnified Party”). The Indemnified Party shall give the indemnifying Party prompt written notice (an “Indemnification Claim Notice”) of any Losses or discovery of fact upon which such Indemnified Party intends to base a request for indemnification under this Article 9, but in no event shall the indemnifying Party be liable for any Losses that result from any delay in providing such notice. Each Indemnification Claim Notice must contain a description of the claim and the nature and amount of such Loss (to the extent that the nature and amount of such Loss is known at such time). The Indemnified Party shall furnish promptly to the indemnifying Party copies of all papers and official documents received in respect of any Losses and Third Party Claims. The indemnifying Party shall have the right to assume the defense of any such Third Party Claim, including the right to select counsel of its choosing and the right to compromise or settle any Third Party Claim, by giving written notice to the Indemnified Party within 30 days after the indemnifying Party’s receipt of an Indemnification Claim Notice; provided, however, that the indemnifying Party shall not make any compromise or settlement admitting fault, subjecting the Indemnified Party to injunctive or other relief, adversely affecting the business of the Indemnified Party or any AstraZeneca Indemnitee or Licensee Indemnitee, as applicable, or incurring any liability on the part of the Indemnified Party or any AstraZeneca Indemnitee or Licensee Indemnitee, as applicable, without the Indemnified Party’s prior written consent, such consent not to be unreasonably withheld or delayed. The Indemnified Party shall be entitled to retain counsel of its choice (at its own expense) to participate in, but not control, the defense of any Third Party Claim. Except as provided in the immediately preceding sentence, the costs and expenses, including fees and disbursements of counsel, incurred by the Indemnified Party and any AstraZeneca Indemnitee or Licensee Indemnitee, as applicable, in connection with any Third Party Claim shall be reimbursed on a Calendar Quarter basis by the indemnifying Party. If the indemnifying Party is required to defend any Third Party Claim, the Indemnified Party shall, and shall cause its employees and agents to, cooperate in the defense or prosecution thereof and shall furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith.

 

 

9.4

Special, Indirect and Other Losses. Except (a) in the event of the gross negligence, willful misconduct or fraud of a Party (or in the case of Licensee, its Sublicensees or Distributors) or of a Party’s breach of its obligations under Article 7 or, with respect to Licensee, Article 3, or (b) to the extent any damages are required to be paid to a Third Party as part of a Third Party claim for which a Party provides indemnification under this Article 9, neither Party nor any of its Affiliates shall be liable to the other Party in contract, tort, negligence, breach of statutory duty or otherwise for any special or punitive damages or for loss of profits suffered by the other Party.

 

9.5

Insurance. Licensee shall have and maintain such types and amounts of insurance covering its Exploitation of the Licensed Compounds and Licensed Products as is (a) normal and customary in the pharmaceutical industry generally for parties similarly situated and (b) otherwise required by Applicable Law.

 

10.	TERM AND TERMINATION

 

10.1

Term and Expiration. This Agreement shall commence on the Effective Date and shall continue in full force and effect until terminated in accordance herewith (such period, the “Term”). Licensee acknowledges and agrees that AstraZeneca will notify [***] that completion of the Transaction (as defined in the [***] Letter Agreement) has taken place on or shortly after, but not before, the License Effective Date.

 

10.2

Termination.

 

10.2.1

Termination by AstraZeneca for Payment Default. If AstraZeneca has not received the Upfront Payment from Licensee within the time stipulated for such payment in Section 5.1.1, then notwithstanding anything else set out in this Agreement, AstraZeneca shall have the right to terminate this Agreement effective immediately upon written notice of termination to Licensee. Upon such termination, notwithstanding anything else set out herein, this Agreement shall end and be of no further effect and the Parties shall be released and discharged from their respective obligations under this Agreement, provided that such termination of this Agreement shall be without prejudice to any claim AstraZeneca may have against Licensee for its breach of this Agreement.

 

 

10.2.2

Material Breach. If either Party materially breaches any of its obligations under this Agreement (such Party, the “Breaching Party”), in addition to any other right and remedy the other Party (the “Non-Breaching Party”) may have, the Non-Breaching Party may terminate this Agreement by providing 90 days’ (or, with respect to a payment breach, 10 days’) (the “Notice Period”) prior written notice (the “Termination Notice”) to the Breaching Party and specifying the breach and its claim of right to terminate; provided that the termination shall not become effective at the end of the Notice Period if the Breaching Party cures the breach specified in the Termination Notice during the Notice Period.

 

10.2.3

Termination by AstraZeneca. If Licensee or any of its Affiliates or Sublicensees, anywhere in the Territory, institutes, prosecutes or otherwise participates in (or in any way aids any Third Party in instituting, prosecuting or participating in), at law or in equity or before any administrative or regulatory body, including the U.S. Patent and Trademark Office or its foreign counterparts, any claim, demand, action or cause of action for declaratory relief, damages or any other remedy or for an enjoinment, injunction or any other equitable remedy, including any interference, re-examination, opposition or any similar proceeding, alleging that any claim in a AstraZeneca Patent is invalid, unenforceable or otherwise not patentable or would not be infringed by Licensee’s activities absent the rights and licenses granted hereunder, AstraZeneca shall have the right to immediately terminate this Agreement in its entirety, including the rights of any Sublicensees, upon written notice to Licensee.

 

10.2.4

Termination for Cessation of Development. In circumstances where both (i) the Licensee ceases development of all Licensed Compounds and all Licensed Products, and (ii) a Licensed Product is not being commercialized in the Territory by or on behalf of Licensee, AstraZeneca shall have the right to terminate this Agreement in its entirety by providing thirty (30) days’ prior written notice to Licensee; provided that the normal pauses or gaps between or following clinical studies or other studies for the analysis of data, preparation of reports and design of future clinical studies or preparation of regulatory filings and other customary development functions not constituting clinical studies do not constitute a cessation of development.

 

 

10.2.5

Termination by Licensee. Licensee may terminate this Agreement for convenience, on a Licensed Product-by-Licensed Product basis or in whole, upon reasonable notice to AstraZeneca. In addition, Licensee may upon written notice thereof to AstraZeneca cease its activities under any Development Plan if the Licensee determines (i) that for scientific, safety, or for ethical reasons, it is inappropriate to continue or (ii) the Licensee determines that a Licensed Product no longer meets an unmet medical need and the Agreement shall upon AstraZeneca’s receipt of such notice be deemed to have been terminated for convenience by Licensee with respect to the relevant Licensed Product(s).

 

10.2.6

Termination for Insolvency. If either Party or any of its Affiliates (a) files for protection under bankruptcy or insolvency laws, or is placed into bankruptcy or receivership, (b) makes an assignment for the benefit of creditors, (c) appoints or suffers appointment of a receiver, liquidator, trustee or administrator or administrative receiver (or equivalent officer) over it or substantially all of its undertaking or property, (d) proposes a written agreement of composition or extension of its debts, (e) proposes or is a party to any dissolution or liquidation, (f) files a petition under any bankruptcy or insolvency act or has any such petition filed against that is not discharged within 60 days of the filing thereof, (g) admits in writing its inability generally to meet its obligations as they fall due in the general course, (h) is otherwise unable to pay its debts as they fall due or (i) ceases or threatens to cease to carry on business; then the other Party may terminate this Agreement in its entirety effective immediately upon written notice to such Party.

 

10.3

Rights in Bankruptcy. All rights and licenses granted under or pursuant to this Agreement by Licensee or AstraZeneca are and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, licenses of right to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code. The Parties agree that the Parties, as licensees of such rights under this Agreement, shall retain and may fully exercise all of their rights and elections under the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against either Party under the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, the Party that is not a party to such proceeding shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, which, if not already in the non-subject Party’s possession, shall be promptly delivered to it (a) upon any such commencement of a bankruptcy proceeding upon the non-subject Party’s written request therefor, unless the Party subject to such proceeding elects to continue to perform all of its obligations under this Agreement or (b) if not delivered under clause (a) above, following the rejection of this Agreement by or on behalf of the Party subject to such proceeding upon written request therefor by the non-subject Party.

 

 

10.4

Consequences of Termination.

 

10.4.1

Termination in its Entirety. In the event of a termination of this Agreement in its entirety for any reason:

 

(a)

all rights and licenses granted by AstraZeneca hereunder shall immediately terminate, provided that (i) the licenses granted under Section 2.1 shall continue to the extent solely as required for Licensee to wind-down or complete any ongoing clinical study in accordance with Section 10.4.1(c) and (ii) any Sublicenses granted by Licensee pursuant to Section 2.2 shall be governed by Section 10.4.1(b);

 

(b)

the following shall apply with regard to any Sublicensee who has been granted a Sublicense by Licensee pursuant to Section 2.2: Upon written notice to AstraZeneca and at the option of any Sublicensee not in breach of the applicable Sublicense (or any provision of this Agreement applicable to such Sublicensee) such Sublicensee will, from the effective date of such termination, automatically become a direct licensee of AstraZeneca under, and subject to the terms and conditions of, this Agreement, subject only to modifications with respect to territory, field and exclusivity consistent with the scope of the applicable Sublicense and so as to accommodate all such Sublicensees. Such Sublicensees will have the right to grant further sublicenses to Third Parties of same or lesser scope as its sublicense from Licensee under the licenses contained in Section 2.1, provided that such further sublicenses will be in accordance with and subject to all of the terms and conditions of Section 2.2 (i.e., such Sublicensee shall be subject to Section 2.2 in the same manner and to the same extent as Licensee). For clarity, any Third Party to whom a Sublicensee grants a sublicense as permitted by the terms of this Agreement shall be deemed to be a Sublicensee for purposes of this Agreement;

 

 

(c)

subject always to Applicable Laws and applicable regulatory requirements, the following shall apply with respect to any ongoing clinical trial of a Licensed Product: (1) where the termination is by AstraZeneca pursuant to Section 10.2.2, 10.2.3, 10.2.4, or 10.2.6, or by Licensee pursuant to Section 10.2.5 (such termination, a “Licensee Triggered Termination”), Licensee shall wind-down such clinical trial or, if AstraZeneca has the right to Exploit such Licensed Products, upon AstraZeneca’s written request, transfer control to AstraZeneca of such clinical trial; and (2) where the termination is not a Licensee Triggered Termination, Licensee shall at its election either wind-down or complete such clinical trial (in accordance with the protocol for such clinical trial).

 

(d)

where the termination is a Licensee Triggered Termination and if and to the extent requested by AstraZeneca in writing within thirty (30) days of the effective date of termination:

 

(i)

Licensee will grant an exclusive, worldwide, sublicensable (through multiple tiers of licensees) license to AstraZeneca under the Licensee Know-How, Licensee Patents and Licensee’s interest in the Joint Patents and Joint Know-How to Exploit the Licensed Compounds and Licensed Products in the Territory, on terms that are commercially reasonable and customary for such license, to be negotiated by the Parties in good faith and recorded in a written license agreement to be signed by the Parties (a “Grant Back License”). If the Parties have not, within ninety (90) days following AstraZeneca’s request (or such longer period as the Parties may agree), signed a Grant Back License, then the matter may be referred by either Party to the Senior Officers for resolution. If the Senior Officers have not within forty-five (45) days after the matter was first referred to them, agreed such terms and if no Grant Back License has been executed by the Parties within such 45 day period, then either Party may, by written notice thereof to the other Party no later than fifteen (15) days after the expiry of such 45 day period, refer the matter for resolution in accordance with the procedure set out in Schedule 10.4.1(d)(i) (and the dispute resolution procedure at Section 11.6.2 shall not apply); and

 

 

(ii)

subject to the Parties having signed a Grant Back License pursuant to Section 10.4.1(d)(i) (whether following good faith negotiations, following escalation to the Senior Officers or through the processes set out in Schedule 10.4.1(d)(i)) the Licensee shall, solely to the extent agreed in the Grant Back License:

 

(1)

assign to AstraZeneca all Licensed Product Agreements, unless, with respect to any such Licensed Product Agreement, such Licensed Product Agreement (A) expressly prohibits such assignment, in which case Licensee (or such Affiliate or Sublicensee, as applicable) shall cooperate with AstraZeneca in all reasonable respects to secure the consent of the applicable Third Party to such assignment, or (B) relates both to Licensed Products and products other than Licensed Products, in which case, at AstraZeneca’s request, Licensee (or such Affiliate or Sublicensee, as applicable) shall cooperate with AstraZeneca in all reasonable respects to secure the written agreement of the applicable Third Party to a partial assignment of the applicable Licensed Product Agreement relating to the Licensed Products, and, in either case ((A) or (B)) if any such consent cannot be obtained with respect to a Licensed Product Agreement, Licensee shall, and shall cause its Affiliates and its and their Sublicensees to, obtain for AstraZeneca substantially all of the practical benefit and burden under such Licensed Product Agreement, including by (AA) entering into appropriate and reasonable alternative arrangements on terms agreeable to AstraZeneca and (BB) subject to the consent and control of AstraZeneca, enforcing, at AstraZeneca’s cost and expense and for the account of AstraZeneca, any and all rights of Licensee (or such Affiliate or Sublicensee, as applicable) against the other party thereto arising out of the breach or cancellation thereof by such other party or otherwise;

 

 

(2)

assign to AstraZeneca all of its right, title and interest in and to (A) any Product Trademark(s) and (B) all Regulatory Documentation (including any Regulatory Approvals) applicable to any Licensed Compounds or Licensed Products then Controlled by Licensee or any of its Affiliates; provided that if any such Regulatory Documentation or Regulatory Approval is not immediately transferable in a country, Licensee would provide AstraZeneca with all the benefit of such Regulatory Documentation or Regulatory Approval, as applicable, and such assistance and cooperation as necessary or reasonably requested by AstraZeneca to timely transfer such Regulatory Documentation or Regulatory Approval, as applicable, to AstraZeneca or its designee or, at AstraZeneca’s option, to enable AstraZeneca to obtain a substitute for such Regulatory Documentation or Regulatory Approval, as applicable, without disruption to AstraZeneca’s Exploitation of the Licensed Compounds or applicable Licensed Product(s), and Licensee would continue to maintain such Regulatory Documentation (including any Regulatory Approvals) at AstraZeneca’s cost and expense unless and until AstraZeneca notifies Licensee that such maintenance is no longer required;

 

(3)

provide AstraZeneca with copies of all reports and data generated or obtained by Licensee or any of its Affiliates and Controlled by Licensee or any of its Affiliates that relate to the Licensed Compounds or any Licensed Product that have not previously been provided to AstraZeneca;

 

(4)

transfer to AstraZeneca such quantities of Licensee’s, its and its Affiliates’ existing inventory of Licensed Compounds or Licensed Products as AstraZeneca requests. The cost to AstraZeneca for such transfer shall be Licensee’s cost to acquire or Manufacture, as applicable, such Licensed Compounds or Licensed Products;

 

 

(5)

use its Commercially Reasonable Efforts to supply to AstraZeneca such quantities of the Licensed Compounds and Licensed Products as AstraZeneca indicates in written forecasts and orders therefor from time to time at Licensee’s cost to Manufacture such Licensed Compounds and Licensed Products (plus a commercially reasonable margin) until the later of (A) such time as AstraZeneca has established an alternate, validated source of supply for the Licensed Compounds and Licensed Products and AstraZeneca is receiving supply from such alternative source and (B) the first anniversary of the effective date of termination of this Agreement; and

 

(6)

provide AstraZeneca with such assistance as is reasonably necessary to effectuate a smooth and orderly transition of any development and commercialization activities with respect to the Licensed Compounds and the Licensed Products to AstraZeneca or its designee so as to minimize any disruption of such activities.

 

10.4.2

Termination in relation to a certain Licensed Product. Upon termination of this Agreement in respect of one or more Licensed Products (but not in relation to all Licensed Products), the consequences set out in Section 10.4.1 shall apply mutatis mutandis solely with respect to the Licensed Product(s) (and all Licensed Compounds included in such Licensed Product(s)), in respect of which the Agreement has been terminated.

 

10.5

Remedies. Except as otherwise expressly provided herein, termination of this Agreement in accordance with the provisions hereof shall not limit remedies that may otherwise be available in law or equity.

 

10.6

Accrued Rights; Surviving Obligations. Termination or expiration of this Agreement for any reason shall be without prejudice to any rights that shall have accrued to the benefit of a Party prior to such termination or expiration. Such termination or expiration shall not relieve a Party from obligations that are expressly indicated to survive the termination or expiration of this Agreement. Without limiting the foregoing, Sections 1, 2.5, 6.1, 7 (for the time period set forth therein), 9, 10.4, 10.5, 10.6, and 11 shall survive the termination or expiration of this Agreement for any reason.

 

 

11.	MISCELLANEOUS

 

11.1

Force Majeure. Neither Party shall be held liable or responsible to the other Party or be deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement (other than an obligation to make payments) to the extent such failure or delay is caused by or results from events beyond the reasonable control of the non-performing Party, including fires, floods, earthquakes, hurricanes, embargoes, shortages, epidemics, quarantines, war, acts of war (whether war be declared or not), terrorist acts, insurrections, riots, civil commotion, acts of God or acts, omissions or delays in acting by any governmental authority (except to the extent such delay results from the breach by the non- performing Party or any of its Affiliates of any term or condition of this Agreement). The non- performing Party shall notify the other Party of such force majeure within ten (10) days after such occurrence by giving written notice to the other Party stating the nature of the event, its anticipated duration and any action being taken to avoid or minimize its effect. The suspension of performance shall be of no greater scope and no longer duration than is necessary and the non-performing Party shall use commercially reasonable efforts to remedy its inability to perform. Without limitation to the foregoing, if the suspension of performance continues for ninety (90) days after the date of the occurrence and such suspension of performance would constitute a material breach of this Agreement in the absence of this Section 11.1, AstraZeneca shall have the right to terminate this Agreement pursuant to Section 10.2.1 without regard to this Section 11.1, except that in such event no cure period shall apply and AstraZeneca shall have the right to effect such termination upon written notice to Licensee, in its sole discretion.

 

11.2

Export Control. This Agreement is made subject to any restrictions concerning the export of products or technical information from the United States or other countries that may be imposed on the Parties from time to time. Each Party agrees that it will not export, directly or indirectly, any technical information acquired from the other Party under this Agreement or any products using such technical information to a location or in a manner that at the time of export requires an export license or other governmental approval, without first obtaining the written consent to do so from the appropriate agency or other governmental entity in accordance with Applicable Law.

 

 

11.3

Assignment. Neither Party may assign its rights or, except as provided in Section 4.12, delegate its obligations under this Agreement, whether by operation of law or otherwise, in whole or in part without the prior written consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed, except that AstraZeneca shall have the right, without such consent, to (i) perform any or all of its obligations and exercise any or all of its rights under this Agreement through any of its Affiliates and (ii) assign any or all of its rights and delegate any or all of its obligations under this Agreement to any of its Affiliates, or any Person who acquires any Licensed Compound or Licensed Product. All validly assigned rights shall inure to the benefit of and be enforceable by, and all validly delegated obligations of such Party shall be binding on and be enforceable against, the permitted successors and assigns of such Party; provided that such Party, if it survives, shall remain jointly and severally liable for the performance of such delegated obligations under this Agreement. Any attempted assignment or delegation in violation of this Section 11.3 shall be void and of no effect.

 

11.4

Severability. If any provision of this Agreement is held to be illegal, invalid or unenforceable under any present or future law and if the rights or obligations of either Party under this Agreement will not be materially and adversely affected thereby, (a) such provision shall be fully severable, (b) this Agreement shall be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable provision or by its severance herefrom and (d) in lieu of such illegal, invalid or unenforceable provision, there shall be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in terms to such illegal, invalid or unenforceable provision as may be possible and reasonably acceptable to the Parties. To the fullest extent permitted by Applicable Law, each Party hereby waives any provision of law that would render any provision hereof illegal, invalid or unenforceable in any respect.

 

11.5

Dispute Resolution.

 

11.5.1

Subject to Section 11.10, if a dispute arises between the Parties in connection with or relating to this Agreement or any document or instrument delivered in connection herewith (a “Dispute”), then either Party shall have the right to refer such Dispute to the Senior Officers for attempted resolution by good faith negotiations during a period of ten (10) Business Days. Any final decision mutually agreed to by the Senior Officers in writing shall be conclusive and binding on the Parties.

 

11.5.2

If such Senior Officers are unable to resolve any such Dispute within such ten (10) Business Day period, either Party shall be free to institute litigation in accordance with Section 11.6.

 

 

11.6

Governing Law, Jurisdiction and Service.

 

11.6.1

Governing Law. This Agreement shall be governed by and construed in accordance with the laws of England and Wales, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction.

 

11.6.2

Jurisdiction. Subject to Section 10.4.1(d)(i) and Section 11.10, the Parties hereby irrevocably and unconditionally consent to the exclusive jurisdiction of the English courts for any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this Agreement and agree not to commence any action, suit or proceeding (other than appeals therefrom) related thereto except in such courts.

 

11.6.3

Venue. The Parties further hereby irrevocably and unconditionally waive any objection to the laying of venue of any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this Agreement in the courts of England and hereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum.

 

11.6.4

Service. Each Party further agrees that service of any process, summons, notice or document by registered mail to its address set forth in Section 11.7.2 shall be effective service of process for any action, suit or proceeding brought against it under this Agreement in any such court.

 

11.7

Notices.

 

11.7.1

Notice Requirements. Any notice, request, demand, waiver, consent, approval or other communication permitted or required under this Agreement shall be in writing, shall refer specifically to this Agreement and shall be deemed given only if delivered by hand or sent by e-mail (with transmission confirmed) or by internationally recognized overnight delivery service that maintains records of delivery, addressed to the applicable Party at its respective addresses specified in Section 11.7.2 or to such other address as the Party to whom notice is to be given may have provided to the other Party in accordance with this Section 11.7.1. Such notice shall be deemed to have been given as of the date delivered by hand or transmitted by e-mail (with transmission confirmed) or on the second Business Day (at the place of delivery) after deposit with an internationally recognized overnight delivery service. Any notice delivered by e-mail shall be confirmed by a hard copy delivered as soon as practicable thereafter. This Section 11.7.1 is not intended to govern the day-to-day business communications necessary between the Parties in performing their obligations under the terms of this Agreement.

 

 

11.7.2

Address for Notice.

 

If to Licensee, to:

 

4995 Murphy Canyon Road

Suite 300

San Diego

California

Attention: CEO

E-mail: [***]

 

with a copy (which shall not constitute notice) to: 

[***] and [***]

 

If to AstraZeneca, to:

 

AstraZeneca AB (PUBL)

SE-431 83 Mölndal,

Sweden

Attention: Head of Business Development and Licensing, Biopharmaceuticals R&D

E-mail: [***]

 

with a copy (which shall not constitute notice) to:

 

AstraZeneca UK Limited

Corporate Legal

Middlewood Court, Silk Road Macclesfield, Cheshire

SK10 2NA

E-mail: [***]

Attention: Assistant General Counsel

 

11.8

Entire Agreement; Amendments. This Agreement, together with the Schedules attached hereto, sets forth and constitutes the entire agreement and understanding between the Parties with respect to the subject matter hereof and all prior agreements, understandings, promises and representations, whether written or oral, with respect thereto are superseded hereby. Each Party confirms that it is not relying on any representations or warranties of the other Party except as specifically set forth in this Agreement. No amendment, modification, release or discharge shall be binding on the Parties unless in writing and duly executed by authorized representatives of both Parties. In the event of any inconsistencies between this Agreement and any schedules or other attachments hereto, the terms of this Agreement shall control.

 

 

11.9

English Language. This Agreement shall be written and executed in and all other communications under or in connection with this Agreement shall be in, the English language. Any translation into any other language shall not be an official version thereof and in the event of any conflict in interpretation between the English version and such translation, the English version shall control.

 

11.10

Equitable Relief. Notwithstanding any other term of this Agreement, where a Party wishes to apply for interim or interlocutory relief in relation to any breach or anticipatory breach of the provisions of this Agreement, the non-breaching Party shall be entitled to seek the same from any court of competent jurisdiction.

 

11.11

Waiver and Non-Exclusion of Remedies. Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition. The waiver by either Party of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party whether of a similar nature or otherwise. The rights and remedies provided herein are cumulative and do not exclude any other right or remedy provided by Applicable Law or otherwise available except as expressly set forth herein.

 

11.12

Further Assurance. Each Party shall duly execute and deliver or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as the other Party may reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes hereof or to better assure and confirm unto such other Party its rights and remedies under this Agreement.

 

11.13

Relationship of the Parties. It is expressly agreed that AstraZeneca, on the one hand and Licensee, on the other hand, shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither AstraZeneca, on the one hand, nor Licensee, on the other hand, shall have the authority to make any statements, representations or commitments of any kind or to take any action, that will be binding on the other Party, without the prior written consent of the other Party to do so. All persons employed by a Party shall be employees of such Party and not of the other Party and all costs and obligations incurred by reason of any such employment shall be for the account and expense of such first Party.

 

 

11.14

References. Unless otherwise specified, (a) references in this Agreement to any Article, Section or Schedule shall mean references to such Article, Section or Schedule of this Agreement, (b) references in any Section to any clause are references to such clause of such Section and (c) references to any agreement, instrument or other document in this Agreement refer to such agreement, instrument or other document as originally executed or, if subsequently amended, replaced or supplemented from time to time, as so amended, replaced or supplemented and in effect at the relevant time of reference thereto.

 

11.15

Construction. Except where the context otherwise requires, wherever used, the singular shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or). Whenever this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. The captions of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The term “including,” “include,” or “includes” as used herein shall mean including, without limiting the generality of any description preceding such term. The language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against either Party.

 

11.16

Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may be executed by PDF format via email or other industry standard electronically transmitted signatures and such signatures shall be deemed to bind each Party as if they were original signatures.

 

[SIGNATURE PAGE FOLLOWS]

 

 

THIS AGREEMENT IS EXECUTED by an authorized representatives of each Party as of the date first written above.

 

Signed by			/s/ Regina Fritsche Danielson
Name:	Regina Fritsche Danielson		Authorised signatory
Title:	SVP Head of Early CVRM
for and on behalf of ASTRAZENECA AB (PUBL)
Signed by			/s/ David Tapolczay
David Tapolczay, Chief Executive Officer, for and on behalf of CONDUIT PHARMACEUTICALS INC.			Authorised signatory

 

 

 

Exhibit 10.32

 

SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE SUCH TERMS ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THESE REDACTED TERMS HAVE BEEN MARKED IN THIS EXHIBIT WITH THREE ASTERISKS [***].

 

STOCK ISSUANCE AGREEMENT

 

This Stock Issuance Agreement (“Agreement”) is entered into as of August 7, 2024, by and between AstraZeneca AB (PUBL), a company incorporated in Sweden under no. 556011-7482 having offices at SE-431 83 Mölndal, Sweden (“AstraZeneca”), and Conduit Pharmaceuticals Inc., a Delaware corporation having offices at 4995 Murphy Canyon Road, Suite 300, San Diego, California (“Conduit” and together with AstraZeneca, the “Parties” and each, a “Party”). The capitalized terms used herein and not otherwise defined have the meanings given to them in Appendix 1 or the License Agreement.

 

Recitals

 

Subject to and in accordance with the terms and provisions of this Agreement, Conduit has agreed to issue, and AstraZeneca has agreed to receive, in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act, 9,504,465 shares (the “Shares”) of Conduit’s common stock, par value $0.0001 per share (the “Common Stock”), as partial consideration for the rights licensed to Conduit from AstraZeneca pursuant to that certain License Agreement, by and between Conduit and AstraZeneca, dated as of the date hereof (the “License Agreement”), the value of which Conduit has determined as of the date hereof exceeds the par value of the Shares to be issued hereunder.

 

Agreement

 

For good and valuable consideration, the Parties agree as follows:

 

Section 1. Stock Issuance.

 

1.1 Issuance and Acquisition of Stock. Subject to the terms and conditions of this Agreement, at the closing of the issuance of the Shares hereunder which is expected to occur on August 8, 2024 or such other date as mutually agreed by Conduit and AstraZeneca, but in no event later than the second (2nd) Business Day following the date hereof (the “Closing”), Conduit will issue to AstraZeneca, and AstraZeneca will receive and accept from Conduit, the Shares as partial consideration for the rights AstraZeneca licensed to Conduit pursuant to the License Agreement.

 

1.2 Book Entry. Upon the Closing, Conduit shall instruct its transfer agent to register the Shares in book entry form in AstraZeneca’s name on Conduit’s share register, free and clear of all restrictive and all other legends (except as expressly provided in Section 4.2 hereof) and shall cause its transfer agent to prepare and deliver to AstraZeneca an account statement reflecting the issuance as promptly as possible following the Closing and, in any event, by no later than five (5) Business Days following the Closing.

 

Section 2. Representations and Warranties of Conduit.

 

Conduit hereby represents and warrants as of the date hereof and as of the Closing to AstraZeneca that:

 

2.1 Private Placement. Neither Conduit nor any Person acting on its behalf, has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under any circumstances that would require registration of the offer and issuance of the Shares under the Securities Act, including by engaging in any form of general solicitation or general advertising in connection with the offer and issuance of the Shares. Subject to the accuracy of the representations and warranties made by AstraZeneca in Section 3, the Shares will be issued and sold to AstraZeneca in compliance with applicable exemptions from the registration and prospectus delivery requirements of the Securities Act and the registration and qualification requirements of all applicable securities laws of the states of the United States. Conduit has not engaged any brokers, finders or agents, or incurred, or will incur, directly or indirectly, any liability for brokerage or finder’s fees or agents’ commissions or any similar charges in connection with this Agreement and the transactions contemplated hereby.

 

 

2.2 Organization and Qualification. Conduit is duly incorporated, validly existing and in good standing under the laws of the State of Delaware, with full corporate power and authority to conduct its business as currently conducted. Conduit is duly qualified to do business and is in good standing in every jurisdiction in which the nature of the business conducted by it or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would not reasonably be expected to (i) have a material adverse effect on the business, assets, liabilities, financial condition, results of operations, or stockholders’ equity of Conduit and its subsidiaries, taken as a whole, or (ii) materially affect the validity of the Shares or materially affect the legal authority of Conduit to comply in all material respects with this Agreement (clauses (i) and (ii), a “Material Adverse Effect”).

 

2.3 Authorization; Enforcement. Conduit has all requisite corporate power and authority to enter into and to perform its obligations under this Agreement, to consummate the transactions contemplated hereby and to issue the Shares in accordance with the terms hereof. The execution, delivery and performance of this Agreement by Conduit and the consummation by it of the transactions contemplated hereby (including the issuance of the Shares at the Closing in accordance with the terms hereof) have been duly authorized by the Board and no further consent or authorization of Conduit, the Board, or the stockholders of Conduit is required. This Agreement has been duly executed by Conduit and constitutes a legal, valid and binding obligation of Conduit enforceable against Conduit in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, or moratorium or similar laws affecting creditors’ and contracting parties’ rights generally and except as enforceability may be subject to general principles of equity and except as rights to indemnity and contribution may be limited by state or federal securities laws or public policy underlying such laws.

 

2.4 Issuance of Shares. The Shares are duly authorized and, upon issuance in accordance with the terms of this Agreement, will be validly issued, fully paid and non-assessable and will be issued free and clear of any liens or other restrictions (other than (i) those under applicable state and federal securities laws and (ii) as set forth in Section 4.2) and will not be subject to preemptive rights or other similar rights of stockholders of Conduit.

 

2.5 No Conflicts; Government Consents and Permits.

 

(a) The execution, delivery and performance of this Agreement by Conduit and the consummation by Conduit of the transactions contemplated hereby (including the issuance of the Shares) will not (i) conflict with or result in a violation of any provision of Conduit’s Second Amended and Restated Certificate of Incorporation or Amended and Restated Bylaws (the “Organizational Documents”), (ii) violate or conflict with, or result in a breach of any provision of, or constitute a default under, any agreement, indenture, or instrument to which Conduit or any of its subsidiaries is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including United States federal and state securities laws and regulations and regulations of any self-regulatory organizations) applicable to Conduit, except in the case of clauses (ii) and (iii) only, for such conflicts, breaches, defaults, and violations as would not reasonably be expected to have a Material Adverse Effect.

 

 

(b) Conduit is not required to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency or any regulatory or self-regulatory agency in order for it to execute, deliver or perform any of its obligations under this Agreement in accordance with the terms hereof, or to issue and sell the Shares in accordance with the terms hereof other than such as have been made or obtained, and except for (i) any post-closing filings required to be made under federal or state securities laws, and (ii) any required filings or notifications regarding the issuance or listing of additional shares with Nasdaq.

 

2.6 Brokers or Finders Fees. No broker, finder, investment banker, or other Person is entitled to any brokerage, finder’s or other similar fee or commission from Conduit in connection with the transactions contemplated by this Agreement or the License Agreement.

 

2.7 Capitalization.

 

(a) The authorized capital stock of Conduit conforms as to legal matters to the description thereof contained in the 2024 SEC Filings. The shares of Common Stock outstanding prior to the issuance of the Shares have been duly authorized and, upon issuance, will be validly issued, fully paid and non-assessable.

 

(b) Except as described in the 2024 SEC Filings, there are no contracts, agreements or understandings between Conduit and any Person granting such Person the right to require Conduit to file a registration statement under the Securities Act with respect to any securities of Conduit and no person other than AstraZeneca has the right (exercisable now or in the future and whether contingent or not) to call for the issuance of any securities of Conduit.

 

(c) The Common Stock has been registered pursuant to Section 12(b) of the Exchange Act and is authorized for trading on the Nasdaq under the trading symbol “CDT”. Conduit has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Stock under the Securities Act or the listing of the Common Stock on Nasdaq, and, except as described in the 2024 SEC Filings (as defined below), Conduit has not received any notification that the SEC or Nasdaq is contemplating terminating such registration or listing.

 

2.8 Subsidiaries. Conduit does not have any material subsidiaries other than the entity listed on Exhibit 21.1 of Conduit’s Annual Report on Form 10-K for the year ended December 31, 2023 (which Exhibit is incorporated by reference as specified in such Annual Report on Form 10-K).

 

2.9 Litigation. Except as described in the 2024 SEC Filings, there is no action, suit, notice of violation, proceeding or investigation pending (of which Conduit has received notice or otherwise has knowledge) or, to the knowledge of Conduit, threatened against Conduit, except where such action, suit, proceeding or investigation, as the case may be, would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

2.10 Financial Statements. The financial statements included in the 2024 SEC Filings, together with the related notes and schedules, comply as to form in all material respects with generally accepted accounting principles, as applied in the United States (“GAAP”) and the rules and regulations of the SEC with respect thereto as in effect at the time of filing (or, to the extent corrected by a subsequent restatement, at the time of such restatement) and present fairly, in all material respects, the consolidated financial position of Conduit and its subsidiaries as of the dates shown and its consolidated results of operations and cash flows for the periods shown, and such financial statements have been prepared in conformity with GAAP applied on a consistent basis during the periods involved (except as may be disclosed therein or in the notes thereto, and, in the case of quarterly financial statements, as permitted by Quarterly Report on Form 10-Q and Regulation S-X under the Exchange Act).

 

2.11 Filings; Reporting Issuer. Conduit has timely filed all SEC Documents (as defined below) required to be filed by it with the SEC under the Exchange Act for the one year preceding the date hereof. As of their respective dates, such SEC Documents (a) complied as to form in all material respects with the applicable requirements of the Exchange Act, and the rules and regulations of the SEC promulgated thereunder applicable to such SEC Documents, and (b) did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.

 

 

2.12 Internal Controls; Disclosure Controls and Procedures. Conduit is in compliance in all material respects with the applicable provisions of the Sarbanes-Oxley Act of 2002, as amended (“Sarbanes-Oxley”) and all applicable rules of The Nasdaq Stock Market, except as disclosed in the 2024 SEC Filings. Conduit maintains internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that are designed to provide reasonable assurances regarding the reliability of the financial reporting and the preparation of financial statements of Conduit for external purposes in accordance with GAAP. Conduit has implemented disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) required in order for the principal executive officer and principal financial officer of Conduit to engage in the review and evaluation process mandated by the Exchange Act. Each of the principal executive officer and the principal financial officer of Conduit has made all certifications required by Sections 302 and 906 of Sarbanes-Oxley with respect to the SEC Documents.

 

2.13 Absence of Changes. Since March 31, 2024: (a) there has not been: (i) a Material Adverse Effect, (ii) any changes to the Organizational Documents or (iii) any declaration, setting aside or payment or other distribution in respect of any shares in the capital of Conduit, or any direct or indirect redemption, purchase, or other acquisition of any of such shares by Conduit; and (b) Conduit has not admitted in writing its inability to pay its debts generally as they become due, filed or consented to the filing against it of a petition in bankruptcy or a petition to take advantage of any insolvency Law, made an assignment for the benefit of creditors, consented to the appointment of a receiver for itself or for the whole or any substantial part of its property, or had a petition in bankruptcy filed against it, been adjudicated a bankrupt, or filed a petition or answer seeking reorganization or arrangement under the United States federal bankruptcy or insolvency Laws.

 

2.14 Investment Company Act. Neither Conduit nor any of its subsidiaries is, and immediately after issuance of the Shares hereunder, neither Conduit nor any of its subsidiaries will be, an “investment company” or an entity “controlled” by an “investment company,” within the meaning of the Investment Company Act of 1940, as amended.

 

2.15 Compliance with Laws and Permits.

 

(a) Conduit and its subsidiaries are, and since January 1, 2023 have been, in compliance with all applicable Laws applicable to their businesses, including all Laws applicable to the research, nonclinical and clinical testing, development, manufacturing, ownership, operation, storage, import, export, warehousing, packaging, and handling of pharmaceutical products, except where the failure to be so in compliance would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. Since January 1, 2023, neither Conduit nor any of its subsidiaries has received any written notice of any violation or alleged violation of any such applicable Laws, from any Governmental Authority, except for such violations or alleged violations that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

(b) Conduit and its subsidiaries have obtained and are in compliance in all material respects with all permits, licenses, franchises, approvals, authorizations and registrations issued or granted by Governmental Authorities that are required for the conduct by Conduit and its subsidiaries of their respective businesses and ownership of their respective properties (each, a “Company Permit”). No proceeding is pending or, to the knowledge of Conduit, threatened to revoke, suspend, cancel, terminate, or adversely modify any such Company Permit, except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

 

(c) None of Conduit or its subsidiaries or, to the knowledge of Conduit, any director, employee or other Person acting on behalf of Conduit or any of its subsidiaries, has (i) taken any action in furtherance of an offer, payment, promise to pay, or authorization or approval of the payment or giving of money, property, gifts or anything else of value, directly or indirectly, to any “government official” (including any officer or employee of a government or government-owned or controlled entity or of a public international organization, or any Person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office) to improperly influence official action or secure an improper advantage for the benefit of Conduit; (ii) violated in any material respect the United States Foreign Corrupt Practices Act of 1977, as amended, any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom, or any other applicable anti-bribery or anti-corruption Law; or (iii) made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any payoff, influence payment, kickback or other unlawful or improper payment or benefit.

 

(d) The operations of Conduit and its subsidiaries are and have been conducted at all times in material compliance with all applicable financial recordkeeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT ACT), and the applicable anti-money laundering statutes of jurisdictions where Conduit and its subsidiaries conduct business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the “Anti-Money Laundering Laws”), and no action, suit or proceeding by or before any court or Governmental Agency, authority or body or any arbitrator involving Conduit or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of Conduit, threatened.

 

(e) (i) Neither Conduit nor any of its subsidiaries, nor, to the knowledge of Conduit, any director, officer, or employee, agent, Affiliate or representative of Conduit or any of its subsidiaries, is an individual or entity (“Company Person”) that is, or is owned or controlled by a Company Person that is: (A) the subject of any sanctions administered or enforced by the U.S. Department of Treasury’s Office of Foreign Assets Control, the United Nations Security Council, the European Union, His Majesty’s Treasury, or other relevant sanctions authority (collectively, “Sanctions”), nor (B) located, organized or resident in a country or territory that is the subject of Sanctions, and (ii) for the past three years, Conduit and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any Company Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions.

 

2.16 Intellectual Property. Conduit and its subsidiaries own, or have valid, binding and enforceable licenses or other rights under the patents and patent applications, copyrights, trademarks, trademark registrations, service marks, service mark registrations, trade names, service names and know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures) and all other technology and intellectual property rights necessary for, or used in the conduct of, their respective businesses (collectively, “Intellectual Property”). The Intellectual Property of Conduit and its subsidiaries has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part. No action, suit, or other proceeding is pending, or, to the knowledge of Conduit, is threatened: (a) challenging Conduit’s or its subsidiaries’ rights in or to any Intellectual Property, (b) challenging the validity, enforceability or scope of any Intellectual Property or (c) alleging that Conduit or any of its subsidiaries infringes, misappropriates, or otherwise violates any patent, trademark, trade name, service name, copyright, trade secret or other proprietary rights of others. Conduit and its subsidiaries have complied in all material respects with the terms of each agreement pursuant to which Intellectual Property has been licensed to Conduit or any of its subsidiaries, and to the knowledge of Conduit, all such agreements are in full force and effect. To the knowledge of Conduit, there are no material defects in any of the patents or patent applications included in the Intellectual Property. Conduit and its subsidiaries have taken reasonable steps to protect, maintain and safeguard their Intellectual Property.

 

 

Section 3. Representations and Warranties of AstraZeneca.

 

AstraZeneca hereby represents and warrants as of the date hereof and as of the Closing to Conduit that:

 

3.1 Authorization; Enforcement. AstraZeneca has the requisite corporate or other similar power and authority to enter into this Agreement and to consummate the transactions contemplated hereby. AstraZeneca has taken all necessary corporate or other similar action to authorize the execution, delivery and performance of this Agreement. Upon the execution and delivery of this Agreement, this Agreement will constitute a valid and binding obligation of AstraZeneca enforceable against AstraZeneca in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting parties’ rights generally and except as enforceability may be subject to general principles of equity and except as rights to indemnity and contribution may be limited by state or federal securities laws or public policy underlying such laws.

 

3.2 No Conflicts; Government Consents and Permits.

 

(a) The execution, delivery and performance of this Agreement by AstraZeneca and the consummation by AstraZeneca of the transactions contemplated hereby (including the receipt and acceptance of the Shares) will not (i) conflict with or result in a violation of any provision of AstraZeneca’s charter documents, bylaws, or other organizational documents, (ii) violate or conflict with, or result in a breach of any provision of, or constitute a default under, any agreement, indenture, or instrument to which AstraZeneca is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including U.S. federal and state securities laws and regulations and regulations of any self-regulatory organizations) applicable to AstraZeneca, except in the case of clauses (ii) and (iii) only, for such conflicts, breaches, defaults, and violations as would not reasonably be expected to have a material adverse effect on the business, assets, liabilities, financial condition, results of operations, or stockholders’ equity of AstraZeneca and its subsidiaries, taken as a whole.

 

(b) AstraZeneca is not required to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency or any regulatory or self-regulatory agency in order for it to execute, deliver or perform any of its obligations under this Agreement in accordance with the terms hereof, or to acquire the Shares in accordance with the terms hereof other than such as have been made or obtained.

 

3.3 Investment Purpose. AstraZeneca is acquiring the Shares for its own account and not with a present view toward the public distribution thereof and has no arrangement or understanding with any other Persons regarding the distribution of such Shares except as would not result in a violation of the Securities Act and without prejudice to AstraZeneca’s right at all times to sell or otherwise dispose of all or any part of the Shares in compliance with applicable United States federal and state securities laws. AstraZeneca will not, directly or indirectly, offer, sell, pledge, transfer or otherwise dispose of (or solicit any offers to buy, purchase or otherwise acquire or take a pledge of) any of the Shares except in accordance with the Securities Act.

 

3.4 Reliance on Exemptions. AstraZeneca understands that Conduit intends for the Shares to be offered and issued to it in reliance upon specific exemptions from the registration requirements of United States federal and state securities laws and that Conduit is relying upon the truth and accuracy of, and AstraZeneca’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of AstraZeneca set forth herein in order to determine the availability of such exemptions and the eligibility of AstraZeneca to acquire the Shares.

 

 

3.5 Accredited Investor; Access to Information. AstraZeneca is an “accredited investor” as defined in Regulation D under the Securities Act and is knowledgeable, sophisticated and experienced in making, and is qualified to make decisions with respect to investments in shares presenting an investment decision like that involved in the acquisition of the Shares. AstraZeneca has been furnished with, or otherwise had access to, materials relating to the offer and sale of the Shares, that have been requested by AstraZeneca, including, without limitation, Conduit’s public filings made available on the SEC’s electronic data gathering and retrieval system (EDGAR) as of the date hereof (the “SEC Documents”), and AstraZeneca has had the opportunity to review such materials. AstraZeneca has been afforded the opportunity to ask questions of Conduit. Neither such inquiries nor any other investigation conducted by or on behalf of AstraZeneca or its representatives or counsel will modify, amend or affect AstraZeneca’s right to rely on the truth, accuracy and completeness of the SEC Documents and Conduit’s representations and warranties contained in this Agreement.

 

3.6 Restricted Securities. AstraZeneca understands that the Shares will be characterized as “restricted securities” under the U.S. federal securities laws inasmuch as they are being issued by Conduit in a private placement under Section 4(a)(2) of the Securities Act and that under such laws and applicable regulations such Shares may be resold without registration under the Securities Act only in certain limited circumstances.

 

Section 4. Transfer, Resale, Legend.

 

4.1 Transfer or Resale. AstraZeneca understands that:

 

(a) other than as provided by Section 5 hereof, the Shares have not been and are not being registered under the Securities Act or any applicable state securities laws and, consequently, AstraZeneca acknowledges that it may have to bear the risk of owning the Shares for an indefinite period of time because the Shares may not be transferred until (i) the resale of the Shares is registered pursuant to an effective registration statement under the Securities Act; (ii) the Shares are sold or transferred pursuant to Rule 144; or (iii) AstraZeneca has delivered to Conduit an opinion of counsel (in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that the Shares to be sold or transferred may be sold or transferred pursuant to an exemption from registration (other than in compliance with Rule 144);

 

(b) any sale of the Shares made in reliance on Rule 144 may be made only in accordance with the terms of Rule 144 and, if Rule 144 is not applicable, any resale of the Shares under circumstances in which the seller (or the Person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the Securities Act) may require compliance with some other exemption under the Securities Act;

 

(c) Conduit acknowledges and agrees that the combination of AstraZeneca’s receipt and acceptance of the Shares pursuant to this Agreement and its rights pursuant to the License Agreement, taken alone and assuming no further acquisitions of Common Stock by AstraZeneca or any of its subsidiaries or other changes to the relationship of the Parties, does not result in AstraZeneca’s being an “affiliate” of Conduit for purposes of and as defined in Rule 144; and

 

(d) subject to receipt from AstraZeneca by Conduit and Conduit’s transfer agent (the “Transfer Agent”) of customary representations and other documentation reasonably acceptable to Conduit and the Transfer Agent in connection therewith, Conduit shall remove the legend from the book entry position evidencing the Shares issued hereunder and Conduit will, if required by the Transfer Agent, use its best efforts to cause an opinion of Conduit’s counsel to be provided, in a form reasonably acceptable to the Transfer Agent to the effect that the removal of such restrictive legend in such circumstances may be effected under the Securities Act, (1) following the time the Resale Registration Statement is declared effective, or (2) if such Shares have been sold pursuant to Rule 144 or any other applicable exemption from the registration requirements of the Securities Act. If the restrictive legend is no longer required for such Shares pursuant to the foregoing, Conduit shall, in accordance with the provisions of this section and within two (2) Trading Days of any request therefore from AstraZeneca accompanied by such customary and reasonably acceptable representations and other documentation referred to above establishing that the restrictive legend is no longer required, deliver to the Transfer Agent instructions to make a new, unlegended entry for such book entry Shares.

 

 

4.2 Legend. AstraZeneca understands the Shares will bear the restrictive legend in substantially the following form (and a stop-transfer order may be placed against transfer of the Shares):

 

THE SHARES HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT, AN EXEMPTION UNDER THE SECURITIES ACT PURSUANT TO RULE 144 UNDER SUCH ACT, OR A CERTIFICATE AND/OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION WITH RESPECT TO THE SECURITIES UNDER THE SECURITIES ACT IS NOT REQUIRED.

 

Conduit agrees to authorize and instruct the removal of the restrictive legend from the Shares in accordance with and subject to applicable securities law and the conditions set forth in Section 4.1(d).

 

Section 5. Registration Rights.

 

5.1 Definitions. For the purpose of this Section 5:

 

(a) the term “Resale Registration Statement” shall mean a registration statement on Form S-3 (or, if Form S-3 is not then available to Conduit, on such other form as is then available to Conduit) to register for resale the Registrable Shares required to be filed by Section 5.2 below, and shall include any preliminary prospectus, final prospectus, exhibit or amendment included in or relating to such registration statements; and

 

(b) the term “Registrable Shares” means the Shares; provided, however, that a security shall cease to be a Registrable Share upon the earliest to occur of the following: (i) a Resale Registration Statement registering such security under the Securities Act has been declared or becomes effective and such security has been sold or otherwise transferred by the holder thereof pursuant to and in a manner contemplated by such effective Resale Registration Statement, (ii) such security is sold pursuant to Rule 144 under circumstances in which any legend borne by such security relating to restrictions on transferability thereof, under the Securities Act or otherwise, is removed by Conduit, (iii) the first date such security is eligible to be sold pursuant to Rule 144 without any limitation as to volume of sales, holding period and without the holder complying with any method of sale requirements or notice requirements under Rule 144, or (iv) such security shall cease to be outstanding following its issuance.

 

5.2 Registration Procedures. Provided that Conduit is qualified for the use of a Resale Registration Statement, Conduit shall file promptly (and, in any event, within 30 days of Closing (the “Filing Deadline”)) a Resale Registration Statement providing for the registration of, and the sale on a continuous or delayed basis of, all Registrable Shares then held by AstraZeneca pursuant to Rule 415 under the Securities Act. Upon filing the Resale Registration Statement, Conduit shall use its best efforts to cause such Resale Registration Statement to be declared effective by the Effectiveness Deadline, keep such Resale Registration Statement effective with the SEC at all times, re-file such Resale Registration Statement upon its expiration, and cooperate in any amendment or supplementation of the prospectus related to the Resale Registration Statement as may be reasonably requested by Conduit or as otherwise required, until such time as all Registrable Shares that could be sold under the Resale Registration Statement have been sold or are no longer outstanding.

 

 

5.3 Rule 415; Cutback. If the SEC prevents Conduit from including any or all of the Registrable Shares in a Resale Registration Statement due to limitations on the use of Rule 415 under the Securities Act or requires AstraZeneca to be named as an “underwriter,” Conduit shall use its commercially reasonable efforts to persuade, consistent with applicable law, the SEC that the offering contemplated by the Resale Registration Statement is a valid secondary offering and not an offering “by or on behalf of the registrant” as described in Rule 415 and that AstraZeneca is not an “underwriter.” In the event that, despite Conduit’s commercially reasonable efforts and compliance with the terms of this Section 5.3, the SEC refuses to alter its position, Conduit shall (i) remove from the Resale Registration Statement only such portion of the Registrable Shares (the “Cut Back Shares”) and/or (ii) agree to such restrictions and limitations on the registration and resale of the Registrable Shares, in each of (i) and (ii), as the SEC requires to assure Conduit’s compliance with the requirements of Rule 415 (collectively, the “SEC Restrictions”); provided, however, that Conduit shall not agree to name AstraZeneca as an “underwriter” in such Registration Statement without the prior written consent of AstraZeneca. AstraZeneca acknowledges that it shall not have suffered any Losses (as defined below) as to any Cut Back Shares until the date that is five (5) Trading Days following the date that Conduit is eligible to bring effective the registration of such Cut Back Shares in accordance with any SEC Restrictions (such date, the “Restriction Termination Date” of such Cut Back Shares). From and after the Restriction Termination Date applicable to any Cut Back Shares, all of the provisions of this Section 5 shall again be applicable to such Cut Back Shares; provided, however, that the Filing Deadline for the Resale Registration Statement including such Cut Back Shares shall be ten (10) Trading Days after such Restriction Termination Date, and Conduit shall use its commercially reasonable efforts to cause such Resale Registration Statement to become effective as promptly as practicable, but in any event, by the Effectiveness Deadline (provided, however, that for purposes of a Resale Registration Statement registering such Cut Back Shares, references to the “Closing Date” contained in the definition of “Effectiveness Deadline” shall instead be to the “Restriction Termination Date”). Any failure by Conduit to file a Resale Registration Statement by the Filing Deadline or to cause such Resale Registration Statement to become effective by the Effectiveness Deadline shall not otherwise relieve Conduit of its obligations to file or cause to become effective the Resale Registration Statements as set forth in this Section 5.

 

5.4 Prospectus Suspension. AstraZeneca acknowledges that there may be times when Conduit must suspend the use of the prospectus forming a part of the Resale Registration Statement until such time as an amendment to the Resale Registration Statement has been filed by Conduit and declared effective by the SEC, or until such time as Conduit has filed an appropriate report with the SEC pursuant to the Exchange Act. AstraZeneca hereby covenants that it will not sell any Registrable Shares pursuant to said prospectus during the period commencing at the time at which Conduit gives AstraZeneca notice of the suspension of the use of said prospectus and ending at the time Conduit gives AstraZeneca notice that AstraZeneca may thereafter effect sales pursuant to said prospectus; provided, (i) that such suspension periods shall in no event exceed (A) on more than two occasions, a period of more than thirty (30) consecutive Trading Days or (B) more than an aggregate total of sixty (60) Trading Days, in each case in any 12 (twelve) month period, and (ii) the Board has reasonably determined that, in order for such Resale Registration Statement not to contain a material misstatement or omission, an amendment thereto would be needed to include information that would at that time not otherwise be required in a current, quarterly or annual report under the Exchange Act.

 

Section 6. Conditions to Closing.

 

6.1 Conditions to Obligations of Conduit. Conduit’s obligation to complete the issuance of the Shares and deliver the Shares to AstraZeneca is subject to the fulfillment or waiver of the following conditions at or prior to the Closing:

 

(a) Representations and Warranties. The representations and warranties made by AstraZeneca in Section 3 will be true and correct in all material respects as of the Closing Date, except to the extent such representations and warranties are made as of another date, in which case such representations and warranties will be true and correct in all material respects as of such other date, and except in each case where the failure of such representations and warranties to be so true and correct (without giving effect to any limitation as to “materiality” set forth therein) would not reasonably be expected to have a material adverse effect on AstraZeneca’s ability to perform its obligations hereunder or consummate the transactions contemplated hereby.

 

 

(b) Covenants. All covenants and agreements contained in this Agreement to be performed or complied with by AstraZeneca on or prior to the Closing Date shall have been performed or complied with in all material respects.

 

(c) Absence of Litigation. No proceeding challenging this Agreement or the transactions contemplated hereby, or seeking to prohibit, alter, prevent or materially delay the Closing, will have been instituted or be pending before any Governmental Authority.

 

(d) License Agreement. AstraZeneca (or an Affiliate of AstraZeneca) shall have duly executed and delivered the License Agreement to Conduit, and subject to execution by Conduit, such agreement shall be in full force and effect.

 

(e) Nasdaq Qualification. Nasdaq shall have raised no objection to the consummation of the transactions contemplated by this Agreement in the absence of stockholder approval of such transactions.

 

(f) No Governmental Prohibition. The issuance of the Shares by Conduit, and the acquisition of the Shares by AstraZeneca will not be prohibited by any applicable Law or governmental order or regulation.

 

6.2 Conditions to AstraZeneca’s Obligations at the Closing. AstraZeneca’s obligation to complete the acquisition of the Shares is subject to the fulfillment or waiver of the following conditions at or prior to the Closing:

 

(a) Representations and Warranties. The representations and warranties made by Conduit in Section 2 will be true and correct in all material respects as of the Closing Date, except to the extent such representations and warranties are made as of another date, in which case such representations and warranties will be true and correct in all material respects as of such other date, and except in each case where the failure of such representations and warranties to be so true and correct (without giving effect to any limitation as to “materiality” or “Material Adverse Effect” set forth therein) would not reasonably be expected to have a Material Adverse Effect on Conduit’s ability to perform its obligations hereunder or consummate the transactions contemplated hereby.

 

(b) Covenants. All covenants and agreements contained in this Agreement to be performed or complied with by Conduit on or prior to the Closing Date shall have been performed or complied with in all material respects.

 

(c) Transfer Agent Instructions. Conduit will have delivered or caused its transfer agent to deliver the Shares to AstraZeneca.

 

(d) Nasdaq Qualification. Prior to the Closing Date, Conduit shall have taken all actions which are reasonably necessary, including, if applicable, providing appropriate notice to Nasdaq of the transactions contemplated by this Agreement, for the Shares to be listed on Nasdaq and shall have complied with all listing, reporting, filing and other obligations under the rules of Nasdaq and of the SEC with respect to the matters contemplated by this Agreement, and Nasdaq shall have raised no objection to the consummation of the transactions contemplated by this Agreement in the absence of stockholder approval of such transactions. The Common Stock shall not have been suspended, as of the Closing Date, by the SEC or Nasdaq from trading on Nasdaq nor shall any such suspension by the SEC or Nasdaq have been threatened, as of the Closing Date, in writing by the SEC or Nasdaq.

 

 

(e) Absence of Litigation. No proceeding challenging this Agreement or the transactions contemplated hereby, or seeking to prohibit, alter, prevent or materially delay the Closing, will have been instituted or be pending before any Governmental Authority.

 

(f) License Agreement. Conduit shall have duly executed and delivered the License Agreement to AstraZeneca (or an Affiliate of AstraZeneca), and subject to execution by AstraZeneca (or an Affiliate of AstraZeneca), such agreement shall be in full force and effect.

 

(g) No Governmental Prohibition. The issuance of the Shares by Conduit, and the acquisition of the Shares by AstraZeneca will not be prohibited by any applicable Law or governmental order or regulation.

 

Section 7. Governing Law; Miscellaneous.

 

7.1 Use of Name. Except as expressly provided herein, neither Party shall mention or otherwise use the Corporate Name, logo or trademark of the other Party or any of its Affiliates (or any abbreviation or adaptation thereof) in any publication, press release, marketing, investment and promotional material or other form of publicity without the prior written approval of such other Party in each instance. The restrictions imposed by this Section 7.1 shall not prohibit (a) either Party from making any disclosure identifying the other Party to the extent required in connection with its exercise of its rights or obligations under this Agreement and (b) either Party from making any disclosure identifying the other Party that is required by applicable Law or the rules of a stock exchange on which the securities of the disclosing Party are listed (or to which an application for listing has been submitted).

 

7.2 Public Announcements. The Parties have agreed that Conduit may within three Business Days following the effective date of this Agreement issue a press release regarding this Agreement and its subject matter, which press release shall be in accordance with Schedule 7.4 of the License Agreement (the “Agreed Press Release”). Other than the Agreed Press Release, neither Party shall issue any other public announcement, press release or other public disclosure regarding this Agreement or its subject matter without the other Party’s prior written consent, such consent not to be unreasonably withheld, delayed or conditioned, except for any such disclosure that is required by applicable Law or the rules of a stock exchange on which the securities of the issuing Party are listed (or to which an application for listing has been submitted), provided that , to the extent practicable and permitted by applicable Law and the rules of the relevant stock exchange, the issuing Party shall allow the other Party to review a close to final draft of such required disclosure and to make comments on such draft and the issuing Party shall take any reasonable comments provided by the other Party into account in good faith when making such required disclosure.

 

7.3 Governing Law; Submission to Jurisdiction; Waiver of Jury Trial.

 

(a) This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction). Any claim, suit, investigation or other legal proceeding (“Action”) arising out of or related to this Agreement, or the transactions contemplated hereby may be instituted in the federal courts of the United States of America or the courts of the State of Delaware, and each Party irrevocably submits to the exclusive jurisdiction of such courts in any such Action.

 

(b) EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE, EACH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT, INCLUDING ANY EXHIBITS AND SCHEDULES ATTACHED TO THIS AGREEMENT, OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT: (I) NO REPRESENTATIVE OF THE OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT THE OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER IN THE EVENT OF A LEGAL ACTION; (II) EACH PARTY HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER; (III) EACH PARTY MAKES THIS WAIVER KNOWINGLY AND VOLUNTARILY; AND (IV) EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION.

 

 

7.4 Survival. The provisions of Section 5 and the representations and warranties of Conduit and AstraZeneca contained in this Agreement shall survive the Closing and delivery of the Shares.

 

7.5 Counterparts; Electronic Signatures. This Agreement may be executed in counterparts, and each such counterpart hereof will be deemed to be an original instrument, but all such counterparts together will constitute but one agreement. Delivery of an executed counterpart of a signature page of this Agreement by PDF, facsimile or other electronic transmission will be effective as delivery of a manually executed original counterpart of this Agreement.

 

7.6 Headings. The headings of this Agreement are for convenience of reference only, are not part of this Agreement and do not affect its interpretation.

 

7.7 Severability. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable Law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable Law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement. In the event of such invalidity, the Parties will seek to agree on an alternative enforceable provision that preserves the original purpose of this Agreement.

 

7.8 Entire Agreement; Amendments. This Agreement and the appendix attached hereto, and the License Agreement, constitute and contain the complete, final and exclusive understanding and agreement of the Parties, and cancel and supersede any and all prior or contemporaneous negotiations, correspondence, understandings and agreements, whether oral or written, between the Parties respecting the subject matter of this Agreement, and neither Party will be liable or bound to any other Party in any manner by any representations, warranties, covenants, or agreements except as specifically set forth herein or therein. Nothing in this Agreement, express or implied, is intended to confer upon any Party, other than the Parties and their respective successors and assigns, any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided herein. No amendment, modification or supplement of any provision of this Agreement will be valid or effective unless made in writing and signed by a duly authorized officer of each Party.

 

7.9 Notices. All notices, consents, waivers and other communications required or permitted to be given hereunder shall be deemed given (a) the date sent if sent by email (with transmission confirmed), (b) the second Trading Day (at the place of delivery) after deposit with an internationally recognized overnight delivery service, or (c) the fifth Trading Day after mailing if mailed by registered or certified mail, postage prepaid and return receipt requested, in each case (a) – (c) to the addresses set forth below or to such other addresses of which notice shall have been given in accordance with this Section 7.7.

 

	If to Conduit, addressed to:	Conduit Pharmaceuticals Inc.
		4995 Murphy Canyon Road, Suite 300
		San Diego, California 92123
		Attention: David Tapolczay
		E-mail: [***]

 

 

	with a copy:	Thompson Hine LLP
		300 Madison Avenue, 27th Floor
		New York, NY 10017
		Attention: Todd Mason
		E-mail: Todd.Mason@ThompsonHine.com

 

	If to AstraZeneca, addressed to:	AstraZeneca AB (PUBL)
		SE-151 85 Södertälje
		Sweden
		Attention: Global Head of Business Development and Licensing, Biopharmaceuticals R&D

 

	with a copy to:	Deputy General Counsel, Corporate Legal
		E-mail: [***]
		And
		[***] Email: [***]

 

7.10 Successors and Assigns. This Agreement is binding upon and inures to the benefit of the Parties and their successors and assigns. Conduit will not assign this Agreement or any rights or obligations hereunder without the prior written consent of AstraZeneca, and AstraZeneca will not assign this Agreement or any rights or obligations hereunder without the prior written consent of Conduit; provided, however, that AstraZeneca may assign this Agreement together with all of the Shares it then owns (subject to Section 4) to any Affiliate of AstraZeneca and any such assignee may assign the Agreement together with all of the Shares it then owns (subject to Section 4) to AstraZeneca or any Affiliate of AstraZeneca, in any such case, without such consent provided that the assignee agrees to assume AstraZeneca’s obligations under Section 4 of this Agreement.

 

7.11 Third Party Beneficiaries. This Agreement is intended for the benefit of the Parties hereto, their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

7.12 Further Assurances. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.

 

7.13 No Strict Construction. The language used in this Agreement is deemed to be the language chosen by the Parties to express their mutual intent, and no rules of strict construction will be applied against a Party.

 

7.14 Equitable Relief. Conduit recognizes that, if it fails to perform or discharge any of its obligations under this Agreement, any remedy at law may prove to be inadequate relief to AstraZeneca. Conduit therefore agrees that, notwithstanding anything set forth in Section 7.1 to the contrary, AstraZeneca is entitled to seek temporary and permanent injunctive relief or specific performance in any such case from any court having jurisdiction over the Parties. AstraZeneca also recognizes that, if it fails to perform or discharge any of its obligations under this Agreement, any remedy at law may prove to be inadequate relief to Conduit. AstraZeneca therefore agrees that, notwithstanding anything set forth in Section 7.1 to the contrary, Conduit is entitled to seek temporary and permanent injunctive relief or specific performance in any such case from any court having jurisdiction over the Parties.

 

7.15 Expenses. Conduit and AstraZeneca are each liable for, and will pay, their own expenses incurred in connection with the negotiation, preparation, execution and delivery of this Agreement, including, without limitation, attorneys’ and consultants’ fees and expenses.

 

[Remainder of page intentionally left blank.]

 

 

In Witness Whereof, AstraZeneca and Conduit have caused this Agreement to be duly executed as of the date first above written.

 

	AstraZeneca AB (PUBL)
	By:	/s/ Regina Fritsche Danielson
	Name:	Regina Fritsche Danielson
	Its:	SVP Head of Early CVRM
	Conduit Pharmaceuticals Inc.
	By:	/s/ David Tapolczay
	Name:	David Tapolczay
	Its:	Chief Executive Officer

 

[Signature page to Stock Issuance Agreement]

 

 

---